CHAPTER 9
Ischaemic stroke and transient ischaemic attack*


1 Heidelberg, Germany; 2 Paris, France; 3 Newcastle, UK; 4 Nottingham, UK; 5 Krems, Austria; 6 Perugia, Italy; 7 Barcelona, Spain; 8 Lille, France; 9 Debrecen, Hungary; 10 Essen, Germany; 11 Lisbon, Portugal; 12 Mannheim, Germany; 13 Helsinki, Finland; 14 Glasgow, UK; 15 Maastricht, The Netherlands; 16 London, UK; 17 Bern, Switzerland; 18 Lund, Sweden; 19 Rome, Italy; 20 Münster, Germany; 21 Erlangen, Germany; 22 Kuopio, Finland; 23 Moscow, Russia; 24 Göteborg, Sweden; 25 Bergen, Norway; 26 Dresden, Germany; 27 Stockholm, Sweden; 28 Nottingham, UK; 29 Edinburgh, UK

Preface

This article represents the update of the European Stroke Initiative (EUSI) Recommendations for Stroke Management, which were first published in 2000 [1, 2] and subsequently translated into a number of languages, including Spanish, Portuguese, Italian, German, Greek, Turkish, Lithuanian, Polish, Russian, and Mandarin Chinese. The first update of the recommendations was published in 2003 [2]. In 2006, the EUSI decided that a larger group of authors should prepare the next update. In the meantime, a new European Stroke Society, the European Stroke Organisation (ESO), was established and took over the task of updating the guidelines. Accordingly, the new recommendations have been prepared by members of both the former EUSI Recommendations Writing Committee and the ESO (see Appendix). The members of the Writing Group met in Heidelberg, Germany, for 3 days in December 2007 to finalize the new recommendations. The members of the Writing Committee were assigned to six groups covering different topics. Each group was co-chaired by two colleagues, and included up to five further experts. To avoid bias or conflict of interest none of the chairs had major involvement in clinical trials or studies discussed in their respective group. In addition, a detailed conflict of interest disclosure form is on file with the editor of the European Journal of Neurology and attached to the electronic version of this article. However, due to the large number of authors, the detailed disclosures are not listed in the printed article.

These guidelines cover both ischaemic stroke and transient ischaemic attacks (TIAs), which are now considered to be a single entity. If recommendations differ for the two conditions, this will be explicitly mentioned; otherwise the recommendations are valid for both conditions. Separate guidelines exist or are being prepared for intracerebral haemorrhage [3] and subarachnoid haemorrhage. The classes of evidence and levels of recommendations used in these guidelines are defined according to the criteria of the European Federation of Neurological Societies (EFNS) (table 9.1, table 9.2). The article

*The authors have prepared this guideline on behalf of the European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee
Table 9.1 Classification of evidence for diagnostic and for therapeutic measures (from [583]).

<table>
<thead>
<tr>
<th>Evidence classification scheme for a diagnostic measure</th>
<th>Evidence classification scheme for a therapeutic intervention</th>
</tr>
</thead>
</table>
| **Class I** | An adequately powered, prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population or an adequately powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations. The following are required: 
  a. randomization concealment
  b. primary outcome(s) is/are clearly defined
  c. exclusion/inclusion criteria are clearly defined
  d. adequate accounting for dropouts and crossovers with numbers sufficiently low to have a minimal potential for bias; and
  e. relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences |
| A prospective study in a broad spectrum of persons with the suspected condition, using a ‘gold standard’ for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy | |
| **Class II** | Prospective matched-group cohort study in a representative population with masked outcome assessment that meets a–e above or a randomized, controlled trial in a representative population that lacks one criterion a–e |
| A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by ‘gold standard’) compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy | |
| **Class III** | All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment |
| Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation | |
| **Class IV** | Evidence from uncontrolled studies, case series, case reports, or expert opinion |
| Evidence from uncontrolled studies, case series, case reports, or expert opinion | |

Table 9.2 Definitions for levels of recommendation (from [583]).

<table>
<thead>
<tr>
<th>Level</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level A</td>
<td>Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective or harmful for a therapeutic intervention; requires at least one convincing Class I study or at least two consistent, convincing Class II studies</td>
</tr>
<tr>
<td>Level B</td>
<td>Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective, or harmful for a therapeutic intervention; requires at least one convincing Class II study or overwhelming Class III evidence</td>
</tr>
<tr>
<td>Level C</td>
<td>Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective or harmful for a therapeutic intervention; requires at least two Class III studies</td>
</tr>
<tr>
<td>Good Clinical Practice (GCP) points</td>
<td>Recommended best practice based on the experience of the guideline development group. Usually based on Class IV evidence indicating large clinical uncertainty; such GCP points can be useful for health workers</td>
</tr>
</tbody>
</table>
The 'time is brain' concept means that treatment of stroke should be considered as an emergency. Thus, avoiding delay should be the major aim in the pre-hospital phase of acute stroke care. This has far-reaching implications in terms of recognition of signs and symptoms of stroke by the patient or by relatives or bystanders, the nature of first medical contact, and the means of transportation to hospital.

Delays during acute stroke management have been identified at different levels [20]:

- at the population level, due to failure to recognize the symptoms of stroke and contact emergency services
- at the level of the emergency services and emergency physicians, due to a failure to prioritize transport of stroke patients
- at the hospital level, due to delays in neuroimaging and inefficient in-hospital care.

A large amount of time is lost outside the hospital [21]: for stroke patients at a Portuguese university hospital this accounted for 82% of the delay in treatment [22]. Studies that identify demographic, social, cultural, behavioural, and clinical factors associated with longer pre-hospital time may provide targets for educational campaigns [23, 24].

The interval from symptom onset to first call for medical help is the predominant part of pre-hospital delay [25–28]. Major reasons for delayed contact include lack of awareness of stroke symptoms and recognition of their severity, but also denial of the disease and the hope that symptoms would resolve. This suggests that educating the population to recognize stroke symptoms, and changing people's attitudes to acute stroke, may reduce the delay from stroke onset to emergency medical service (EMS) involvement.

Medical attention is rarely sought by the patient: in many cases contact is initially made by a family member [28–30]. Information and educational initiatives should therefore be directed both to persons at high risk of stroke and also to those around them.

Stroke awareness depends on demographic and socio-cultural factors, and on personal medical knowledge. Knowledge of stroke warning signs varies considerably, depending on the symptoms, and is dependent on the way questions are asked (e.g. open-ended or multiple-choice questions [31, 32]).

While most people agree that stroke is an emergency, and that they would seek medical help immediately, in...
Major Neurological Diseases

Most studies show that only approximately 33–50% of patients recognize their own symptoms as stroke. There are considerable discrepancies between theoretical knowledge of stroke and the reaction in case of an acute stroke. Some studies have shown that patients with better knowledge of stroke symptoms do not always arrive earlier at hospital. The most frequently used sources of stroke information are mass media [37–39] and friends and relatives who have knowledge of stroke; only rarely is information derived from general practitioners or books [40–44]. The sources accessed vary with age: older people more often obtain information from health campaigns or their general practitioner, whereas younger people gain more information from TV [38–40].

Interventional studies have measured the effect of education on stroke knowledge. Eight non-randomized studies measured the impact of educational measures on pre-hospital time delay or thrombolysis use [45–52]. In six studies, the intervention was a combined educational programme directed at the public, paramedics, and health professionals, while in two studies education was directed only to the population. Only the TLL Temple Foundation Stroke Project included a concurrent control group [50, 51]. All studies had a pre-post design. Thrombolysis usage increased after education in the intervention group of the TLL study, but only for up to 6 months after intervention ended [51]. This suggests that public education has to be maintained to sustain stroke awareness in the population.

Education should also be directed to paramedics and emergency department (ED) staff to improve the accuracy of stroke identification and speed up transfer to the hospital [53]. Education of paramedics increases stroke knowledge, clinical skills, and communication skills, and decreases prehospital delays [54].

Educating medical students in basic stroke knowledge during their first year at medical school has been shown to be associated with a high degree of knowledge retention [55]. The value of postgraduate training is universally acknowledged, but training programmes for stroke specialists are still heterogeneous throughout Europe. To overcome such heterogeneity and to increase the number of specialists available for stroke care, some countries (e.g., France, UK) have developed and implemented national curricula. In contrast, other countries rely on training specialization within neurology training programmes. With a view towards harmonization of training, a European Masters’ Programme for Stroke Medicine (www.donau-uni.ac.at/en/studium/strokemedicine/index.php) and annual Stroke Summer Schools (www.eso-stroke.org), have been established.

**Referral and patient transfer**

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate EMS contact and priority EMS dispatch are recommended (Class II, Level B).</td>
</tr>
<tr>
<td>Priority transport with advance notification to the receiving hospital (outside and inside hospital) is recommended (Class III, Level B).</td>
</tr>
<tr>
<td>It is recommended that suspected stroke victims should be transported without delay to the nearest medical centre with a stroke unit that can provide ultra-early treatment (Class III, Level B).</td>
</tr>
<tr>
<td>It is recommended that dispatchers and ambulance personnel be trained to recognize stroke using simple instruments such as the Face–Arm–Speech–Test (Class IV, GCP).</td>
</tr>
<tr>
<td>Immediate emergency room triage, clinical, laboratory and imaging evaluation, accurate diagnosis, therapeutic decision, and administration of appropriate treatments at the receiving hospital are recommended (Class III, Level B).</td>
</tr>
<tr>
<td>It is recommended that in remote or rural areas helicopter transfer should be considered in order to improve access to treatment (Class III, Level C).</td>
</tr>
<tr>
<td>It is recommended that in remote or rural areas telemedicine should be considered in order to improve access to treatment (Class II, Level B).</td>
</tr>
<tr>
<td>It is recommended that patients with suspected TIA be referred without delay to a TIA clinic or to a medical centre with a stroke unit that can provide expert evaluation and immediate treatment (Class III, Level B).</td>
</tr>
</tbody>
</table>

Successful care of the acute stroke victim begins with the recognition by both the public and health professionals [56] that stroke is an emergency, like acute myocardial infarction or trauma. However, in practice the majority of ischaemic stroke patients do not receive recombinant tissue plasminogen activator (rtPA) because they do not
reach the hospital soon enough [22, 36, 57, 58]. Emergency care of the acute stroke victim depends on a four-step chain:

- rapid recognition of, and reaction to, stroke signs and TIs
- immediate EMS contact and priority EMS dispatch
- priority transport with notification of the receiving hospital
- immediate emergency room triage, clinical, laboratory and imaging evaluation, accurate diagnosis, and administration of appropriate treatments at the receiving hospital.

Once stroke symptoms are suspected, patients or their proxies should call EMS. The EMS system should have an electronic validated algorithm of questions to diagnose stroke during the phone interview [33, 59]. The ambulance dispatchers and paramedics should be able to diagnose stroke using simple instruments such as the Face–Arm–Speech–Test [60]. They should also be able to identify and provide appropriate help for patients who need urgent care because of early complications or comorbidities of stroke, such as impaired consciousness, seizures, vomiting, or haemodynamic instability.

Suspected stroke victims should be transported without delay to the nearest medical centre with a stroke unit that can provide ultra-early treatment. Patients with onset of stroke symptoms within 3 h should be given priority in evaluation and transportation [20]. In each community, a network of stroke units or, if stroke units are not yet available, a network of medical centres providing organized acute stroke care should be implemented and publicized to the general population, health professionals, and the emergency transport systems [61, 62].

If a doctor receives a call or consultation from a patient with suspected stroke, they should recommend or arrange transportation, preferably through the EMS system, to the nearest hospital with a stroke unit providing organized acute stroke care and ultra-early treatment. Ambulance dispatchers should inform the stroke unit and describe the patient’s clinical status. Proxies who can describe symptom onset or the patient’s medical history should accompany the patient.

Few intervention studies have examined the impact of decreasing the delay from symptom onset to arrival at the hospital and making ultra-early treatment accessible for a larger proportion of patients. Most such studies have used a before-and-after intervention design, were neither randomized nor masked with respect to intervention or evaluation of outcome, and lacked concurrent controls [23, 53]. The types of intervention included education and training programmes, helicopter transfer, telemedicine, and reorganization of pre-hospital and in-hospital protocols for acute stroke patients.

Direct presentation to the ED via ambulance or EMS transportation is the fastest way of referral [28, 53, 63–65]. Helicopter transport can reduce the time between referral and hospital arrival [66, 67], and also promotes access to thrombolytic therapy in remote and rural areas [68]. In mixed rural and urban areas, air and ground distances can be compared using simple rules [69]. No studies have compared air and ground transport specifically in stroke patients. In one study, predominantly in trauma patients, ground ambulances provided shorter arrival times at distances less than 10 miles (=16 km) from the hospital; even with only short delays in dispatching air transport, air was faster only for distances longer than 45 miles (=72 km) [70]. One economic study showed that helicopter transfer of patients with suspected acute ischaemic stroke for potential thrombolysis is cost-effective [71].

Telemedicine using bidirectional video-conferencing equipment to provide health services or assist health care personnel at distant sites is a feasible, valid, and reliable means of facilitating thrombolytic delivery to patients in distant or rural hospitals, where timely air or ground transportation is not feasible. The quality of treatment, complication rates, and short- and long-term outcomes are similar for acute stroke patients treated with rTPA via a telemedicine consultation at local hospitals and those treated in academic centres [72–81].

Activation of the stroke code as a special infrastructure with immediate calling of a stroke neurologist at a stroke unit and priority transfer of the patients to this centre is effective in increasing the percentage of patients treated with thrombolysis, and also in shortening pre-hospital delays [82, 83].

Recent community and hospital-based studies demonstrated a high risk of stroke immediately after a TIA [6, 84]. Observational studies showed that urgent evaluation at a TIA clinic and immediate initiation of treatment reduces stroke risk after TIA [85, 86]. This underlines the need for urgent referral of TIA for expert evaluation and immediate treatment.
Emergency management

Recommendations

• Organization of pre-hospital and in-hospital pathways and systems for acute stroke patients is recommended (Class III, Level C).
• Ancillary tests, as outlined in table 9.3, are recommended (Class IV, GCP).

In-hospital delay may account for 16% of total time lost between stroke onset and computed tomography (CT) [22]. Reasons for in-hospital delays are:
• a failure to identify stroke as an emergency
• inefficient in-hospital transport
• delayed medical assessment
• delay in imaging
• uncertainty in administering thrombolysis [20, 21, 24]. Stroke care pathways may allow care to be organized more effectively, although a meta-analysis [87] did not support their routine implementation. Such pathways may reduce delays in door-to-medical department time, door-to-imaging time [88, 89], door-to-needle time [89] and, where appropriate, door-to-arteriography time.

Acute stroke care has to integrate EMS, ED staff, and stroke care specialists. Communication and collaboration between EMS, ED staff, radiologists, clinical laboratories, and neurologists are important for rapid delivery of treatment [11, 90, 91]. Integrating EMS and ED staff was found to increase the use of thrombolysis [92]. Hospitals where patients are not delivered directly to a stroke unit should implement a system allowing the ED to pre-notify the acute stroke team as soon as possible. Routinely informing ED physicians or stroke physicians during transport has been shown to be associated with reduced in-hospital delay [82, 93-95], increased use of thrombolysis [92, 93], decreased length of hospital stay [95], and decreased in-hospital mortality [92].

A stroke recognition instrument with high diagnostic accuracy is necessary for rapid triage [96]; stroke mimics such as migraine and seizure might be a problem [97, 98]. Stroke recognition instruments such as Face–Arm–Speech–Test and Recognition of Stroke in the Emergency Room (ROSIER) can assist the correct recognition of stroke by ED personnel [60, 97, 99].

A neurologist or stroke physician should be involved in the acute care of stroke patients and available in the ED [98]. Comparing neurologist care to non-neurologist care, two studies in the USA found that neurologists perform more extensive and costly testing, but that their patients had lower in-hospital and 90-day mortality rates, and were less dependent on discharge [100, 101]. However, this might not be true for other countries such as the UK, where most stroke physicians are not neurologists, but are still highly skilled in management of patients with TIA and stroke.

Reorganization of stroke wards can help to avoid bottlenecks and unnecessary in-hospital transport. Brain imaging facilities should be relocated in or next to the stroke unit or the ED, and stroke patients should have priority access [90]. Neuroradiologists should be notified as early as possible [90]. In a Finnish study, in-hospital delays were decreased considerably by moving the CT scanner close to the ED and by implementing a pre-notifyting system [94]. Thrombolysis should be started in the CT room or in the vicinity of the scanner. Finally, an arteriography suite should be readily accessible if endovascular treatment is required.

Written care protocols for acute stroke patients should be available; centres using such protocols were found to have higher thrombolysis rates [92]. Implementing a continuous quality improvement scheme can also diminish in-hospital delays [81, 102]. Benchmarks should be

| Table 9.3 Emergency diagnostic tests in acute stroke patients. |
|------------------|--------------------------------------------------|
| In all patients  | Brain imaging: CT or MRI                        |
|                  | ECG                                             |
|                  | Laboratory tests                                |
|                  | Complete blood count and platelet count, prothrombin time or INR, partial thrombin time (PTT) |
|                  | Serum electrolytes, blood glucose               |
|                  | C-reactive protein (CRP) or sedimentation rate  |
|                  | Hepatic and renal chemical analysis             |
| When indicated  | Excranial and transcranial Duplex/Doppler ultrasound |
|                  | MRA or CTA                                       |
|                  | Diffusion and perfusion MR or perfusion CT      |
|                  | Echocardiography (transthoracic and/or transoesophageal) |
|                  | Chest X-ray                                      |
|                  | Pulse oximetry and arterial blood gas analysis  |
|                  | Lumbar puncture                                  |
|                  | EEG                                             |
|                  | Toxicology screen                               |
Providing stroke services

All acute stroke patients require specialist multidisciplinary care delivered in a stroke unit, and selected patients will require additional high-technology interventions. Health services need to establish the infrastructure to deliver these interventions to all patients who require them: the only reason for excluding patients from stroke units is if their condition does not warrant active management. Recent consensus documents [11, 105] have defined the roles of primary and comprehensive stroke centres (table 9.4).

Primary stroke centres are defined as centres with the necessary staffing, infrastructure, expertise, and programmes to provide appropriate diagnosis and treatment for most stroke patients. Some patients with rare disorders, complex stroke, or multi-organ disease may need more specialized care and resources that are not available in primary stroke centres.

Comprehensive stroke centres are defined as centres that provide both appropriate diagnosis and treatment for most stroke patients, and also high-technology medical and surgical care (new diagnostic and rehabilitation methods, specialized tests, automatic monitoring of multiple physiological parameters, interventional radiology, vascular surgery, neurosurgery).

The organization of clinical networks using telemedicine is recommended to facilitate treatment options not previously available at remote hospitals. Administration of rtPA during telemedicine consultations is feasible and safe [106]. Clinical networks using telemedicine systems achieve increased use of rtPA [80, 107] and better stroke care and clinical outcomes [80].

Stroke unit care

An updated systematic review has confirmed significant reductions in death (3% absolute reduction), dependency (5% increase in independent survivors), and the need for institutional care (2% reduction) for patients treated in a stroke unit, compared with those treated in general wards. All types of patients, irrespective of gender, age, stroke subtype, and stroke severity, appear to benefit from treatment in stroke units [61, 108]. These results have been confirmed in large observational studies of routine practice [109–111]. Although stroke unit care is more costly than treatment on general neurological or medical wards, it reduces post-acute inpatient care costs [112, 113] and is cost-effective [114–117].
A stroke unit consists of a discrete area of a hospital ward that exclusively or nearly exclusively takes care of stroke patients and is staffed by a specialist multidisciplinary team [61]. The core disciplines of the team are medicine, nursing, physiotherapy, occupational therapy, speech and language therapy, and social work [118]. The multidisciplinary team should work in a co-ordinated way through regular meetings to plan patient care. Programmes of regular staff education and training should be provided [118]. The typical components of stroke unit care in stroke unit trials [118] were:

- medical assessment and diagnosis, including imaging (CT, magnetic resonance imaging [MRI]), and early assessment of nursing and therapy needs
- early management, consisting of early mobilization, prevention of complications, and treatment of hypoxia, hyperglycaemia, pyrexia, and dehydration
- ongoing rehabilitation, involving co-ordinated multidisciplinary team care, and early assessment of needs after discharge.

Both acute and comprehensive stroke units admit patients acutely and continue treatment for several days. Rehabilitation stroke units admit patients after 1–2 weeks and continue treatment and rehabilitation for several weeks if necessary. Most of the evidence for effectiveness comes from trials of comprehensive stroke units and rehabilitation stroke units [61, 119]. Mobile stroke teams, which offer stroke care and treatment in a number of wards, probably do not influence important outcomes and cannot be recommended [120]. Such teams have usually been established in hospitals where stroke units were not available.

The stroke unit should be of sufficient size to provide specialist multidisciplinary care for the whole duration of hospital admission. Smaller hospitals may achieve this with a single comprehensive unit, but larger hospitals may require a pathway of care incorporating separate acute and rehabilitation units.

### Diagnostics

#### Diagnostic imaging

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>- In patients with suspected TIA or stroke, urgent cranial CT (Class I), or alternatively MRI (Class II), is recommended (Level A).</td>
</tr>
<tr>
<td>- If MRI is used, the inclusion of diffusion-weighted imaging (DWI) and T2*-weighted gradient echo sequences is recommended (Class II, Level A).</td>
</tr>
<tr>
<td>- In patients with TIA, minor stroke, or early spontaneous recovery immediate diagnostic work-up, including urgent vascular imaging (ultrasound, CT-angiography, or MR angiography) is recommended (Class I, Level A).</td>
</tr>
</tbody>
</table>
Imaging of the brain and supplying vessels is crucial in the assessment of patients with stroke and TIA. Brain imaging distinguishes ischaemic stroke from intracranial haemorrhage and stroke mimics, and identifies the type and often also the cause of stroke; it may also help to differentiate irreversibly damaged tissue from areas that may recover, thus guiding emergency and subsequent treatment, and may help to predict outcome. Vascular imaging may identify the site and cause of arterial obstruction, and identifies patients at high risk of stroke recurrence.

**General principles**

Stroke victims should have clear priority over other patients for brain imaging, because time is crucial. In patients with suspected TIA or stroke, general and neurological examination followed by diagnostic brain imaging must be performed immediately on arrival at the hospital so that treatment can be started promptly. Investigation of TIA is equally urgent, because up to 10% of these patients will suffer stroke within the next 48 h. Immediate access to imaging is facilitated by pre-hospital notification and good communication with the imaging facility; stroke services should work closely with the imaging department to plan the best use of resources.

Diagnostic imaging must be sensitive and specific in detecting stroke pathology, particularly in the early phase of stroke. It should provide reliable images, and should be technically feasible in acute stroke patients. Rapid, focused neurological assessment is helpful to determine which imaging technique should be used. Imaging tests should take into account the patient's condition [121]; for example, up to 45% of patients with severe stroke may not tolerate MR examination because of their medical condition and contraindications [122–124].

**Imaging in patients with acute stroke**

Patients admitted within 3 h of stroke onset may be candidates for intravenous (i.v.) thrombolysis [125]; CT is usually sufficient to guide routine thrombolysis. Patients arriving later may be candidates for trials testing extended time windows for thrombolysis or other experimental reperfusion strategies.

Plain CT is widely available, reliably identifies most stroke mimics, and distinguishes acute ischaemic from haemorrhagic stroke within the first 5–7 days [126–128]. Immediate CT scanning is the most cost-effective strategy for imaging acute stroke patients [129], but is not sensitive for old haemorrhage. Overall, CT is less sensitive than MRI, but equally specific, for early ischaemic changes [130]. Two-thirds of patients with moderate to severe stroke have visible ischaemic changes within the first few hours [130–134], but no more than 50% of patients with minor stroke have a visible relevant ischaemic lesion on CT, especially within the first few hours of stroke [135]. Training in identification of early ischaemic changes on CT [134, 136, 137], and the use of scoring systems [133], improve detection of early ischaemic changes.

Early CT changes in ischaemic stroke include decreases in tissue X-ray attenuation, tissue swelling with effacement of cerebrospinal fluid spaces, and arterial hyperattenuation, which indicates the presence of intraluminal thrombus with high specificity [138]. CT is highly specific for the early identification of ischaemic brain damage [131, 139, 140]. The presence of early signs of ischaemia on CT should not exclude patients from thrombolysis within the first 3 h, though patients with a hypoattenuating ischaemic lesion which exceeds one-third of the middle cerebral artery (MCA) territory may benefit less from thrombolysis [125, 133, 134, 141, 142].

Some centres prefer to use MRI as first-line routine investigation for acute stroke. MRI with diffusion-weighted imaging (DWI) has the advantage of higher sensitivity for early ischaemic changes than CT [130]. This higher sensitivity is particularly useful in the diagnosis of posterior circulation stroke and lacunar or small cortical infarctions. MRI can also detect small and old haemorrhages for a prolonged period with T2* (gradient echo) sequences [143]. However, DWI can be negative in patients with definite stroke [144].

Restricted diffusion on DWI, measured by the apparent diffusion coefficient (ADC), is not 100% specific for ischaemic brain damage. Although abnormal tissue on DWI often proceeds to infarction it can recover, which indicates that DWI does not show only permanently damaged tissue [145, 146]. Tissue with only modestly reduced ADC values may be permanently damaged; there is as yet no reliable ADC threshold to differentiate dead from still viable tissue [147, 148]. Other MRI sequences (T2, FLAIR, T1) are less sensitive in the early detection of ischaemic brain damage.
MRI is particularly important in acute stroke patients with unusual presentations, stroke varieties, and uncommon aetiologies, or in whom a stroke mimic is suspected but not clarified on CT. If arterial dissection is suspected, MRI of the neck with fat-suppressed T1-weighted sequences is required to detect intramural haematoma.

MRI is less suited for agitated patients or for those who may vomit and aspirate. If necessary, emergency life support should be continued while the patient is being imaged, as patients (especially those with severe stroke) may become hypoxic while supine during imaging [124]. The risk of aspiration is increased in the substantial proportion of patients who are unable to protect their airway.

Perfusion imaging with CT or MRI and angiography may be used in selected patients with ischaemic stroke (e.g. unclear time window, late admission) to aid the decision on whether to use thrombolysis, although there is no clear evidence that patients with particular perfusion patterns are more or less likely to benefit from thrombolysis [149–152]. Selected patients with intracranial arterial occlusion may be candidates for intra-arterial thrombolysis, although there is only limited evidence to support this [153, 154]. Patients with combined obstructions of the internal carotid artery (ICA) and MCA have less chance of recovering with i.v. thrombolysis than patients with isolated MCA obstructions [155]. In patients with MCA trunk occlusions, the frequency of severe extracranial occlusive disease in the carotid distribution is high [156, 157].

Mismatch between the volume of brain tissue with critical hypoperfusion (which can recover after reperfusion) and the volume of infarcted tissue (which does not recover even with reperfusion) can be detected with MR diffusion/perfusion imaging with moderate reliability [158], but this is not yet a proven strategy for improving the response to thrombolysis up to 9 h [159]. There is disagreement on how to best identify irreversible ischaemic brain injury and to define critically impaired blood flow [149, 152, 160]. Quantification of MR perfusion is problematic [161], and there are widely differing associations between perfusion parameters and clinical and radiological outcomes [149]. Decreases in cerebral blood flow on CT are associated with subsequent tissue damage [150, 151], but the therapeutic value of CT perfusion imaging is not yet established. Although infarct expansion may occur in a high proportion of patients with mismatch, up to 50% of patients without mismatch may also have infarct growth and so might benefit from tissue salvage [152, 162]. The ‘imaging/clinical’ mismatch, i.e. the mismatch between the extent of the lesion seen on DWI or CT and the extent of the lesion as expected from the severity of the neurological deficit, has produced mixed results [163, 164]. Hence, neither perfusion imaging with CT or MRI nor the mismatch concept can be recommended for routine treatment decisions.

Microhaemorrhages are present on T2* MRI in up to 60% of patients with haemorrhagic stroke, and are associated with older age, hypertension, diabetes, leukoaraiosis, lacunar stroke, and amyloid angiopathy [165]. The incidence of symptomatic intracranial haemorrhage following thrombolysis in ischaemic stroke patients was not increased in those having cerebral microbleeds on pre-treatment T2*-weighted MRI [166].

Vascular imaging should be performed rapidly to identify patients with tight symptomatic arterial stenosis who could benefit from endarterectomy or angioplasty. Non-invasive imaging with colour-coded duplex imaging of the extracranial and intracranial arteries, CT angiography (CTA), or contrast-enhanced MR angiography (CE-MRA) is widely available. These approaches are relatively risk-free, whereas intra-arterial angiography has a 1–3% risk of causing stroke in patients with symptomatic carotid lesions [167, 168]. Digital subtraction angiography (DSA) may be needed in some circumstances, for example when other tests have been inconclusive.

Carotid ultrasound, MRA, and CTA visualise carotid stenosis. Systematic reviews and individual patient data meta-analysis indicate that CE-MRA is the most sensitive and specific non-invasive imaging modality for carotid artery stenosis, closely followed by Doppler ultrasound and CTA, with non-contrast MRA being the least reliable [169, 170].

Some data suggest that vertebrobasilar TIA and minor stroke is associated with a high risk of recurrent stroke [171]. Extracranial vertebral ultrasound diagnosis is useful, but intracranial ultrasound of the vertebrobasilar system can be misleading due to low specificity. Limited data suggest that CE-MRA and CTA offer better non-invasive imaging of the intracranial vertebral and basilar arteries [172].

Unlike other imaging modalities ultrasound is fast, non-invasive, and can be administered using portable
CHAPTER 9  Acute stroke

machines. It is therefore applicable to patients unable to co-operate with MRA or CTA [157]. However, Doppler studies alone often provide only limited information, are investigator-dependent and require skilled operators, although they allow repeated measurements at the bedside.

Transcranial Doppler ultrasound (TCD) is useful for the diagnosis of abnormalities in the large cerebral arteries at the base of the skull. However, between 7 and 20% of acute stroke patients, particularly elderly individuals and those from certain ethnic groups do not have an adequate acoustic window [173, 174]. This problem can be considerably reduced by using ultrasound contrast agents, which also allow perfusion studies in the acute phase [175–177] and continuous monitoring of cerebral haemodynamic responses [178]. The combination of ultrasound imaging techniques and MRA reveals excellent results equal to DSA [179]. Cerebral reactivity and cerebral autoregulation are impaired in patients with occlusive extracerebral arterial disease (particularly carotid stenosis and occlusion) and inadequate collateral supply, who are at increased risk of recurrent stroke [180, 181]. TCD is the only technique that detects circulating intracranial emboli [182], which are particularly common in patients with large artery disease. In patients with symptomatic carotid artery stenoses, they are a strong independent predictor of early recurrent stroke and TIA [183], and have been used as a surrogate marker to evaluate antiplatelet agents [184]. TCD microbubble detection can be used to identify a right-to-left shunt, which mainly results from a patent foramen ovale (PFO) [185].

Imaging in patients with TIA, minor non-disabling stroke, and stroke with spontaneous recovery

Patients presenting with TIA are at high risk of early recurrent stroke (up to 10% in the first 48 h) [186]. They therefore need urgent clinical diagnosis to treat associated general abnormalities, modify active risk factors, and identify specific treatable causes, particularly arterial stenosis and other embolic sources. Vascular imaging is a priority in those patients with TIA or minor stroke, more than in those with major stroke in whom surgery is not going to be of benefit in the short term. Immediate preventive treatment will reduce stroke, disability, and death [86, 187]. Simple clinical scoring systems can be used to identify patients at particularly high risk [186]. Patients with minor non-disabling stroke and rapid spontaneous clinical recovery are also at high risk of recurrent stroke [58].

Patients with widely varying brain pathology may present with transient neurological deficits indistinguishable from TIA. CT reliably detects some of these pathologies (e.g. intracerebral haemorrhage, subdural haematoma, tumours) [129], but others (e.g. multiple sclerosis, encephalitis, hypoxic brain damage, etc.) are better identified on MRI, while others (e.g. acute metabolic disturbances) are not visible at all. Intracranial haemorrhage is a rare cause of TIA.

Between 20 and 50% of patients with TIAs may have acute ischaemic lesions on DWI [144, 188, 189]. These patients are at increased risk of early recurrent disabling stroke [189]. However, there is currently no evidence that DWI provides better stroke prediction than clinical risk scores [190]. The risk of recurrent disabling stroke is also increased in patients with TIA and an infarct on CT [191].

The ability of DWI to identify very small ischaemic lesions may be particularly helpful in patients presenting late or in patients with mild non-disabling stroke, in whom the diagnosis may be difficult to establish on clinical grounds [130]. T2*-MRI is the only reliable method to identify haemorrhages after the acute phase, when blood is no longer visible on CT [143].

Other diagnostic tests

Recommendations

- In patients with acute stroke and TIA, early clinical evaluation, including physiological parameters and routine blood tests, is recommended (Class I, Level A).
- For all stroke and TIA patients, a sequence of blood tests is recommended (table 9.3, table 9.5).
- It is recommended that all acute stroke and TIA patients should have a 12-lead ECG. In addition continuous ECG recording is recommended for ischaemic stroke and TIA patients (Class I, Level A).
- It is recommended that for stroke and TIA patients seen after the acute phase, 24-h Holter ECG monitoring should be performed when arrhythmias are suspected and no other causes of stroke are found (Class I, Level A).
- Echocardiography is recommended in selected patients (Class III, Level B).
Cardiac evaluation

Cardiac and ECG abnormalities are common in acute stroke patients [192]. In particular, prolonged QTc, ST depression, and T wave inversion are prevalent in acute ischaemic stroke, especially if the insular cortex is involved [193, 194]. Hence, all acute stroke and TIA patients should have a 12-channel ECG.

Cardiac monitoring should be conducted routinely after an acute cerebrovascular event to screen for serious cardiac arrhythmias. It is unclear whether continuous ECG recording at the bedside is equivalent to Holter monitoring for the detection of atrial fibrillation (AF) in acute stroke patients. Holter monitoring is superior to routine ECG for the detection of AF in patients anticipated to have thromboembolic stroke with sinus rhythm [195]; however, serial 12-channel ECG might be sufficient to detect new AF in a stroke unit setting [196]. A recent systematic review found that new AF was detected by Holter ECG in 4.6% of patients with recent ischaemic stroke or TIA, irrespective of baseline ECG and clinical examination [197]. Extended duration of monitoring, prolonged event loop recording, and confining Holter monitoring to patients with non-lacunar stroke, may improve detection rates [198].

Echocardiography can detect many potential causes of stroke [199], but there is controversy about the indications for, and type of, echocardiography in stroke and TIA patients. Transoesophageal echocardiography (TOE) has been claimed to be superior to transthoracic echocardiography (TTE) for the detection of potential cardiac sources of embolism [200], independent of age [201].

Echocardiography is particularly required in patients with:

- evidence of cardiac disease on history, examination, or ECG
- suspected cardiac source of embolism (e.g. infarctions in multiple cerebral or systemic arterial territories)
- suspected aortic disease
- suspected paradoxical embolism
- no other identifiable causes of stroke.

TTE is sufficient for evaluation of mural thrombi, particularly in the apex of the left ventricle; this technique has >90% sensitivity and specificity for ventricular thrombi after myocardial infarction [202]. TOE is superior for evaluation of the aortic arch, left atrium, and atrial septum [199]. It also allows risk stratification for further thromboembolic events in patients with AF [203].

The role of cardiac CT and cardiac MRI in the detection of embolic sources in stroke patients has not been evaluated systematically.

Blood tests

Blood tests required on emergency admission are listed in table 9.3. Subsequent tests depend on the type of stroke and suspected aetiology (table 9.5).

Primary prevention

The aim of primary prevention is to reduce the risk of stroke in asymptomatic people. Relative risk (RR), absolute risk (AR), odds ratio (OR), numbers needed to treat (NNT) to avoid one major vascular event per year, and numbers needed to harm (NNH) to cause one major
complication per year are provided for each intervention in tables 9.6–9.8.

Management of vascular risk factors

**Recommendations**
- Blood pressure should be checked regularly. It is recommended that high blood pressure should be managed with lifestyle modification and individualized pharmacological therapy (Class I, Level A) aiming at normal levels of 120/80 mmHg (Class IV, GCP). For prehypertensive (120–139/80–90 mmHg) with congestive heart failure, MI, diabetes, or chronic renal failure, antihypertensive medication is indicated (Class I, Level A).
- Blood glucose should be checked regularly. It is recommended that diabetes should be managed with lifestyle modification and individualized pharmacological therapy (Class IV, Level C). In diabetic patients, high blood pressure should be managed intensively (Class I, Level A) aiming for levels below 130/80 mmHg (Class IV, Level C). Where possible, treatment should include an angiotensin converting enzyme inhibitor or angiotensin receptor antagonist (Class I, Level A).
- Blood cholesterol should be checked regularly. It is recommended that high blood cholesterol (e.g. LDL>150 mg/dl [3.9 mmol/l]) should be managed with lifestyle modification (Class IV, Level C) and a statin (Class I, Level A).
- It is recommended that cigarette smoking be discouraged (Class III, Level B).
- It is recommended that heavy use of alcohol be discouraged (Class III, Level B).
- Regular physical activity is recommended (Class III, Level B).
- A diet low in salt and saturated fat, high in fruit and vegetables and rich in fibre is recommended (Class III, Level B).
- Subjects with an elevated body mass index are recommended to take a weight-reducing diet (Class III, Level B).
- Antioxidant vitamin supplements are not recommended (Class I, Level A).
- Hormone replacement therapy is not recommended for the primary prevention of stroke (Class I, Level A).

A healthy lifestyle, consisting of abstinence from smoking, low–normal body mass index, moderate alcohol consumption, regular exercise and healthy diet, is associated with a reduction in ischaemic stroke (RR 0.29; 95% CI 0.14–0.63) [204].

<table>
<thead>
<tr>
<th>Disease</th>
<th>NNT to avoid one stroke/year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic (60–99%)</td>
<td>85</td>
</tr>
<tr>
<td>Symptomatic (70–99%)</td>
<td>27</td>
</tr>
<tr>
<td>Symptomatic (50–69%)</td>
<td>75</td>
</tr>
<tr>
<td>Symptomatic (≥50%) in men</td>
<td>45</td>
</tr>
<tr>
<td>Symptomatic (≥50%) in women</td>
<td>180</td>
</tr>
<tr>
<td>Symptomatic (≥50%) ≥75 years</td>
<td>25</td>
</tr>
<tr>
<td>Symptomatic (≥50%) &lt;65 years</td>
<td>90</td>
</tr>
<tr>
<td>Symptomatic (≥50%) &lt;2 weeks after the event</td>
<td>25</td>
</tr>
<tr>
<td>Symptomatic (≥50%) &gt;12 weeks after the event</td>
<td>625</td>
</tr>
<tr>
<td>Symptomatic (≤50%) No benefit</td>
<td></td>
</tr>
</tbody>
</table>

High blood pressure

A high (>120/80 mmHg) blood pressure (BP) is strongly and directly related to vascular and overall mortality without evidence of any threshold [205]. Lowering BP substantially reduces stroke and coronary risks, depending on the magnitude of the reduction [206–208]. BP should be lowered to 140/85 mmHg or below [209]; antihypertensive treatment should be more aggressive in diabetic patients (see below) [210]. A combination of two or more antihypertensive agents is often necessary to achieve these targets.

Most studies comparing different drugs do not suggest that any class is superior [206, 207, 211]. However, the LIFE (Losartan Intervention for Endpoint reduction in hypertension) trial found that losartan was superior to atenolol in hypertensive patients with left ventricular hypertrophy (NNT to prevent stroke 270) [212, 213]. Similarly, the ALLHAT (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack) trial found that chlorthalidone was more effective than amlodipine and lisinopril [214]. Beta-blockers may still be considered an option for initial and subsequent antihypertensive treatment [209]. In elderly subjects, controlling isolated systolic hypertension (systolic blood pressure >140 mmHg and diastolic blood pressure <90 mmHg) is beneficial [207, 215].
Table 9.7 Relative risk reduction (RRR), absolute risk reduction (ARR), and number needed to treat (NNT) to avoid one major vascular event per year in patients with antithrombotic therapy (modified from [318, 321, 584]).

<table>
<thead>
<tr>
<th>Disease</th>
<th>Treatment</th>
<th>RRR %</th>
<th>ARR % per year</th>
<th>NNT to avoid one event per year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-cardioembolic ischaemic stroke or TIA</td>
<td>aspirin/PCB</td>
<td>13</td>
<td>1.0</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>aspirin + DIP/PCB</td>
<td>28</td>
<td>1.9</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>aspirin + DIP/aspirin</td>
<td>18</td>
<td>1.0</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>Clop/PCB</td>
<td>23</td>
<td>1.6</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td>Clop/aspirin</td>
<td>10</td>
<td>0.6</td>
<td>166</td>
</tr>
<tr>
<td>Atrial fibrillation (primary prevention)</td>
<td>warfarin/PCB</td>
<td>62</td>
<td>2.7</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>aspirin/PCB</td>
<td>22</td>
<td>1.5</td>
<td>67</td>
</tr>
<tr>
<td>Atrial fibrillation (secondary prevention)</td>
<td>warfarin/PCB</td>
<td>67</td>
<td>8</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>aspirin/PCB</td>
<td>21</td>
<td>2.5</td>
<td>40</td>
</tr>
</tbody>
</table>

PCB: placebo; Clop: clopidogrel; DIP: dipyridamole.

Table 9.8 Relative risk reduction (RRR), absolute risk reduction (ARR), and number needed to treat (NNT) to avoid one major vascular event per year in patients with risk factor modifications (modified from [287, 289, 293, 584]).

<table>
<thead>
<tr>
<th>Clinical condition</th>
<th>Treatment</th>
<th>RRR %</th>
<th>ARR % per year</th>
<th>NNT to avoid one event per year</th>
</tr>
</thead>
<tbody>
<tr>
<td>General population with increased blood pressure</td>
<td>Antihypertensive</td>
<td>42</td>
<td>0.4</td>
<td>250</td>
</tr>
<tr>
<td>General population with increased vascular risk</td>
<td>ACE inhibitor</td>
<td>22</td>
<td>0.65</td>
<td>154</td>
</tr>
<tr>
<td>Post-stroke/TIA with increased blood pressure</td>
<td>Antihypertensive</td>
<td>31</td>
<td>2.2</td>
<td>45</td>
</tr>
<tr>
<td>Post-stroke/TIA with normal blood pressure</td>
<td>ACE inhibitor ± diuretic</td>
<td>24</td>
<td>0.85</td>
<td>118</td>
</tr>
<tr>
<td>Post-stroke/TIA</td>
<td>Statins</td>
<td>16</td>
<td>0.44</td>
<td>230</td>
</tr>
<tr>
<td></td>
<td>Smoking cessation</td>
<td>33</td>
<td>2.3</td>
<td>43</td>
</tr>
</tbody>
</table>

Diabetes mellitus
There is no evidence that improving glucose control reduces stroke [216]. In diabetic patients, blood pressure should be lowered to below 130/80 mmHg [210]. Treatment with a statin reduces the risk of major cardiovascular events, including stroke [217-219].

Hyperlipidaemia
In a review of 26 statin trials (95 000, patients), the incidence of stroke was reduced from 3.4% to 2.7% [220]. This was due mainly to a reduction in non-fatal stroke, from 2.7% to 2.1%. The review included the Heart Protection Study, which was, in part, a secondary prevention trial [221]; this trial found an excess of myopathy of one per 10 000 patients treated per annum [221]. There are no data to suggest that statins prevent stroke in patients with low-density lipoprotein (LDL) cholesterol below 150 mg/dl (3.9 mmol/l).

Cigarette smoking
Observational studies have shown cigarette smoking to be an independent risk factor for ischaemic stroke [222] in both men and women [223–227]. Spousal cigarette smoking may be associated with an increased stroke risk [228]. A meta-analysis of 22 studies indicates that smoking doubles the risk of ischaemic stroke [229]. Subjects who stop smoking reduce this risk by 50% [224]. Making workplaces smoke-free would result in considerable health and economic benefits [230].
CHAPTER 9  Acute stroke

Alcohol consumption
Heavy alcohol drinking (>60 g/day) increases the risk of ischaemic stroke (RR 1.69; 95% CI 1.34–2.15) and haemorrhagic stroke (RR 2.18; 95% CI 1.48–3.20). In contrast, light consumption (<12 g/day) is associated with a reduction in all stroke (RR 0.83; 95% CI 0.75–0.91) and ischaemic stroke (RR 0.80; 95% CI 0.67–0.96), and moderate consumption (12–24 g/day) with a reduction in ischaemic stroke (RR 0.72; 95% CI 0.57–0.91) [231]. Red wine consumption is associated with the lowest risk in comparison with other beverages [232]. Blood pressure elevation appears to be an important intermediary in the relation between alcohol consumption and stroke [233].

Physical activity
In a meta-analysis of cohort and case-control studies, physically active individuals had a lower risk of stroke or death than those with low activity (RR 0.73; 95% CI 0.67–0.79). Similarly, moderately active individuals had a lower risk of stroke, compared with those who were inactive (RR 0.80; 95% CI 0.74–0.86) [234]. This association is mediated, in part, through beneficial effects on body weight, blood pressure, serum cholesterol, and glucose tolerance. Leisure-based physical activity (2 to 5 hours per week) has been independently associated with a reduced severity of ischaemic stroke at admission and better short-term outcome [235].

Diet

Fruit, vegetable, and fish intake
In observational studies, high fruit and vegetable intake was associated with a decreased risk of stroke, compared with lower intake (RR 0.96 for each increment of two servings/day; 95% CI 0.93–1.00) [236]. The risk of ischaemic stroke was lower in people who consumed fish at least once per month (RR 0.69; 95% CI 0.48–0.99) [237]. Whole grain intake was associated with a reduction in cardiovascular disease (OR 0.79; 95% CI 0.73–0.85) but not stroke [238]. Dietary calcium intake from dairy products was associated with lower mortality from stroke in a Japanese population [239]. However, in a further study there was no interaction between the intake of total fat or cholesterol, and stroke risk in men [240].

In a randomized controlled trial in women, dietary interventions did not reduce the incidence of coronary events and stroke despite there being an 8.2% reduction of total fat intake and an increased consumption of vegetables, fruits and grains [241].

Body weight
A high body mass index (BMI ≥25) is associated with an increased risk of stroke in men [242] and women [243], mainly mediated by concomitant arterial hypertension and diabetes. Abdominal adiposity is a risk factor for stroke in men but not women [244]. Although weight loss reduces blood pressure [245], it does not lower stroke risk [246].

Vitamins
A low intake of vitamin D is associated with an increased risk of stroke [247], but supplements of calcium plus vitamin D do not reduce the risk of stroke [248]. Supplements of tocopherol and beta carotene do not reduce stroke [249]. A meta-analysis of trials with vitamin E supplementation found that it might increase mortality when used at high doses (≥400 IU/d) [250].

High homocysteine levels are associated with increased stroke risk (OR 1.19; 95% CI 1.05–1.31) [251]. Since folic acid fortification of enriched grain products was mandated by the US Food and Drug Administration there has been a reduction in stroke mortality rates, in contrast to countries without fortification [252]. A meta-analysis concluded that folic acid supplementation can reduce the risk of stroke (RR 0.82; 95% CI 0.68–1.00) [253]; the benefit was greatest in trials with long treatment durations or larger homocysteine-lowering effects, and in countries where grain was not fortified.

Postmenopausal oestrogen replacement therapy
Stroke rates rise rapidly in women after the menopause. However, in an analysis based on a 16-year follow-up of 59,337 postmenopausal women participating in the Nurses’ Health Study, there was only a weak association between stroke and oestrogen replacement [254]. According to the HERS II trial, hormone replacement in healthy women is associated with an increased risk of ischaemic stroke [255]. A Cochrane systematic review [256] found hormone replacement therapy to be associated with an increased risk of stroke (RR 1.44; 95% CI 1.10–1.89). A secondary analysis of the Women’s Health Initiative randomized controlled trial suggests that the risk of stroke is increased with hormone replacement therapy only in women with prolonged hormone use (> 5 years; RR 1.32; 95% CI 1.12–1.56) [257, 258].
Antithrombotic therapy

**Recommendations**

- Low-dose aspirin is recommended in women aged 45 years or more who are not at increased risk for intracerebral haemorrhage and who have good gastrointestinal tolerance; however, its effect is very small (Class I, Level A).
- It is recommended that low-dose aspirin may be considered in men for the primary prevention of myocardial infarction; however, it does not reduce the risk of ischaemic stroke (Class I, Level A).
- Antiplatelet agents other than aspirin are not recommended for primary stroke prevention (Class IV, GCP).
- Aspirin may be recommended for patients with non-valvular AF who are younger than 65 years and free of vascular risk factors (Class I, Level A).
- Unless contraindicated, either aspirin or an oral anticoagulant (international normalized ratio [INR] 2.0–3.0) is recommended for patients with non-valvular AF who are aged 65–75 years and free of vascular risk factors (Class I, Level A).
- Unless contraindicated, an oral anticoagulant (INR 2.0–3.0) is recommended for patients with non-valvular AF who are aged >75, or who are younger but have risk factors such as high blood pressure, left ventricular dysfunction, or diabetes mellitus (Class I, Level A).
- It is recommended that patients with AF who are unable to receive oral anticoagulants should be offered aspirin (Class I, Level A).
- It is recommended that patients with AF who have mechanical prosthetic heart valves should receive long-term anticoagulation with a target INR based on the prosthesis type, but not less than INR 2–3 (Class II, Level B).
- Low-dose aspirin is recommended for patients with asymptomatic internal carotid artery (ICA) stenosis >50% to reduce their risk of vascular events (Class II, Level B).

**Low-risk subjects**

Six large randomized trials have evaluated the benefits of aspirin for the primary prevention of cardiovascular (CV) events in men and women (47,293 on aspirin, 45,580 controls) with a mean age of 64.4 years [259–264]. Aspirin reduced coronary events and CV events, but not stroke, CV mortality, or all-cause mortality [265]. In women, aspirin reduced stroke (OR 0.83; 95% CI 0.70–0.97) and ischaemic stroke (OR 0.76; 95% CI 0.63–0.93), and caused a non-significant increase in haemorrhagic stroke, over 10 years; it did not reduce the risk of fatal or nonfatal myocardial infarction, or cardiovascular death [267].

No data are currently available on the use of other antiplatelet agents in primary prevention in low-risk subjects.

**Subjects with vascular risk factors**

A systematic review of randomized studies comparing antithrombotic agents with placebo in patients with elevated BP and no prior cardiovascular disease showed that aspirin did not reduce stroke or total cardiovascular events [266]. In the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, the combination of aspirin and clopidogrel was less effective than aspirin alone in the subgroup of patients with multiple vascular risk factors but no ischaemic event [268].

**Large artery atheroma**

Patients with atherosclerotic arterial disease have an increased risk of myocardial infarction, stroke, and cardiovascular death. Aspirin reduces MI in patients with asymptomatic carotid artery disease [269], and reduces stroke after carotid artery surgery [270].

**Atrial fibrillation**

AF is a strong independent risk factor for stroke. A meta-analysis of randomized trials with at least 3 months’ follow-up showed that antiplatelet agents reduced stroke (RR 0.78; 95% CI 0.65–0.94) in patients with non-valvular AF [271]. Warfarin (target INR 2.0–3.0) is more effective than aspirin at reducing stroke (RR 0.36; 95% CI 0.26–0.51) [271]. As the risk of stroke in people with AF varies considerably, risk stratification should be used to determine whether patients should be given oral anticoagulation, aspirin, or nothing [14]. Oral anticoagulation is more effective in patients with AF who have one or more risk factors, such as previous systemic embolism, age over 75 years, high blood pressure, or poor left ventricular function [14]. In the meta-analysis described above, absolute increases in major extracranial haemorrhage were less than the absolute reductions in stroke [271]. The WASPO (Warfarin versus Aspirin for Stroke Prevention in Octogenarians) [272] and BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged)
[273] trials showed that warfarin was safe and effective in older individuals. The ACTIVE W (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events) study found that the combination of aspirin and clopidogrel was less effective than warfarin and had a similar bleeding rate [274].

Patients with a prosthetic heart valve, with or without AF, should receive long-term anticoagulation with a target INR based on the prosthesis type (bio-prosthetic valves: INR 2.0–3.0; mechanical valves: INR 3.0–4.0 [275]).

**Secondary prevention**

### Optimal management of vascular risk factors

**Recommendations**

- It is recommended that blood pressure be checked regularly. Blood pressure lowering is recommended after the acute phase, including in patients with normal blood pressure (Class I, Level A).
- It is recommended that blood glucose should be checked regularly. It is recommended that diabetes should be managed with lifestyle modification and individualized pharmacological therapy (Class IV, GCP).
- In patients with type 2 diabetes who do not need insulin, treatment with pioglitazone is recommended after stroke (Class III, Level B).
- Statin therapy is recommended in subjects with non-cardioembolic stroke (Class I, Level A).
- It is recommended that cigarette smoking be discouraged (Class III, Level C).
- It is recommended that heavy use of alcohol be discouraged (Class IV, GCP).
- Regular physical activity is recommended (Class IV, GCP).
- A diet low in salt and saturated fat, high in fruit and vegetables, and rich in fibre is recommended (Class IV, GCP).
- Subjects with an elevated body mass index are recommended to adopt a weight-reducing diet (Class IV, Level C).
- Antioxidant vitamin supplements are not recommended (Class I, Level A).
- Hormone replacement therapy is not recommended for the secondary prevention of stroke (Class I, Level A).
- It is recommended that sleep-disordered breathing such as obstructive sleep apnoea be treated with continuous positive airway pressure breathing (Class III, Level GCP).
- It is recommended that endovascular closure of PFO be considered in patients with cryptogenic stroke and high risk PFO (Class IV, GCP).
High blood pressure
A meta-analysis of seven randomized controlled trials showed that antihypertensive drugs reduced stroke recurrence after stroke or TIA (RR 0.76; 95% CI 0.63–0.92) [285]. This analysis included the PATS (indapamide, a diuretic), HOPE (ramipril) and PROGRESS (perindopril, with or without indapamide) studies [286–289]. The reduction in stroke occurs regardless of BP and type of stroke [289]. Hence, BP should be lowered and monitored indefinitely after stroke or TIA. The absolute target BP level and reduction are uncertain and should be individualized, but benefit has been associated with an average reduction of about 10/5 mmHg, and normal BP levels have been defined as <120/80 mmHg [290]. However, blood pressure should not be lowered intensively in patients with suspected haemodynamic stroke or in those with bilateral carotid stenosis. The angiotensin receptor antagonist eprosartan may be more effective than the calcium channel blocker nitrendipine [291].

Diabetes mellitus
The prospective, double-blind PROactive trial randomized 5238 patients with type 2 diabetes and a history of macrovascular disease to pioglitazone or placebo. In patients with previous stroke (n = 486 in the pioglitazone group, n = 498 in the placebo group), there was a trend towards benefit with pioglitazone for the combined endpoint of death and major vascular events (HR 0.78; 95% CI 0.60–1.02; p = 0.067). In a secondary analysis, pioglitazone reduced fatal or non-fatal stroke (HR 0.53; 95% CI 0.34–0.85; p = 0.0085) and cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (HR 0.72; 95% CI 0.52–1.00; p = 0.0467) [292].

Hyperlipidaemia
In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, statin therapy with atorvastatin reduced stroke recurrence (HR 0.84; 95% CI 0.71–0.99) [293], while in the Heart Protection Study, simvastatin reduced vascular events in patients with prior stroke, and reduced stroke in patients with other vascular disease (RR 0.76) [221]. Neither trial assessed efficacy by stroke subtype, and SPARCL did not include patients with presumed cardioembolic stroke [221, 293]. The risk of haemorrhagic stroke was slightly increased in both trials [221, 293]. The absolute risk reduction achieved with statin therapy is low (NNT 112–143 for 1 year). Statin withdrawal at the acute stage of stroke may be associated with an increased risk of death or dependency [294].

Cigarette smoking
There are no specific data in secondary prevention. See primary prevention.

Diet
Overweight
There are no specific data in secondary prevention. See primary prevention. Weight loss may be beneficial after stroke as it lowers blood pressure [245].

Vitamins
Beta carotene increased the risk of cardiovascular death in a meta-analysis of primary and secondary prevention trials (RR 1.10; 95% CI 1.03–1.17) [295]. Vitamin E supplementation does not prevent vascular events [296]. Fat-soluble antioxidant supplements may increase mortality [297]. Vitamins that lower homocysteine (folate, B12, B6) do not appear to reduce stroke recurrence and may increase vascular events [298–301], but further trials are ongoing [302].

Sleep-disordered breathing
Sleep-disordered breathing represents both a risk factor and a consequence of stroke and is linked with poorer long-term outcome and increased long-term stroke mortality [303]. More than 50% of stroke patients have sleep-disordered breathing, mostly in the form of obstructive sleep apnoea (OSA). This can improve spontaneously after stroke, but may need treatment. Continuous positive airway pressure is the treatment of choice for OSA. Oxygen and other forms of ventilation may be helpful in other (e.g. central) forms of SDB.

Patent foramen ovale
Case reports and case control studies indicate an association between the presence of PFO and cryptogenic stroke in both younger and older stroke patients [304, 305]. Two population-based studies pointed in the same direction but did not confirm a significant association [306, 307]. In patients with PFO alone, the overall risk of recurrence is low. However, when the PFO is combined with an atrial septal aneurysm, a Eustachian valve, a Chiari network, or in patients who have suffered more
than one stroke, the risk of recurrence can be substantial [308]. Endovascular closure of PFOs with or without septal aneurysms is feasible in such patients [309] and may lower the risk of recurrent stroke compared to medical treatment [310]; however, RCTs are still lacking.

Postmenopausal oestrogen replacement therapy
Hormone replacement therapy does not protect against vascular events and may increase stroke severity [311].

Antithrombotic therapy

Recommendations
- It is recommended that patients receive antithrombotic therapy (Class I, Level A).
- It is recommended that patients not requiring anticoagulation should receive antiplatelet therapy (Class I, Level A). Where possible, combined aspirin and dipyridamole, or clopidogrel alone, should be given. Alternatively, aspirin alone or triflusal alone may be used (Class I, Level A).
- The combination of aspirin and clopidogrel is not recommended in patients with recent ischaemic stroke, except in patients with specific indications (e.g. unstable angina or non-Q-wave MI, or recent stenting); treatment should be given for up to 9 months after the event (Class I, Level A).
- It is recommended that patients who have a stroke on antiplatelet therapy should be re-evaluated for pathophysiology and risk factors (Class IV, GCP).
- Oral anticoagulation (INR 2.0–3.0) is recommended after ischaemic stroke associated with AF (Class I, Level A). Oral anticoagulation is not recommended in patients with comorbid conditions such as falls, poor compliance, uncontrolled epilepsy, or gastrointestinal bleeding (Class III, Level C). Increasing age alone is not a contraindication to oral anticoagulation (Class I, Level A).
- It is recommended that patients with cardioembolic stroke unrelated to AF should receive anticoagulants (INR 2.0–3.0) if the risk of recurrence is high (Class III, Level C).
- It is recommended that anticoagulation should not be used after non-cardioembolic ischaemic stroke, except in some specific situations, such as aortic atheromas, fusiform aneurysms of the basilar artery, cervical artery dissection, or patent foramen ovale in the presence of proven deep vein thrombosis (DVT) or atrial septal aneurysm (Class IV, GCP).
- It is recommended that combined low dose aspirin and dipyridamole should be given if oral anticoagulation is contraindicated (Class IV, GCP).

Antiplatelet therapy
Antiplatelet therapy reduces vascular events, including non-fatal myocardial infarction, nonfatal stroke and vascular death in patients with previous stroke or TIA (RR 0.78; 95% CI 0.76–0.80) [312].

Aspirin
Aspirin reduces recurrence irrespective of dose (50 to 1300 mg/d) [313–316], although high doses (>150 mg/day) increase adverse events. In patients with symptomatic intracranial atherosclerosis, aspirin is as effective as oral anticoagulation and has fewer complications [317].

Clopidogrel
Clopidogrel is slightly more effective than aspirin in preventing vascular events (RR 0.91; 95% CI 0.84–0.97) [318]. It may be more effective in high-risk patients (i.e. those with previous stroke, peripheral artery disease, symptomatic coronary disease, or diabetes) [268].

Dipyridamole
Dipyridamole reduces stroke recurrence with similar efficacy to aspirin [319].

Triflusal
Triflusal reduces stroke recurrence with similar efficacy to aspirin but with fewer adverse events [320].

Dipyridamole plus aspirin
The combination of aspirin (38–300 mg/d) and dipyridamole (200 mg extended release twice daily) reduces the risk of vascular death, stroke or MI, compared with aspirin alone (RR 0.82; 95% CI 0.74–0.91) [319, 321]. Dipyridamole may cause headache; the incidence of this may be reduced by increasing the dose gradually [322, 323].

Clopidogrel plus aspirin
Compared with clopidogrel alone, the combination of aspirin and clopidogrel did not reduce the risk of ischaemic stroke, myocardial infarction, vascular death, or re-hospitalization [324]; however, life-threatening or
major bleeding were increased with the combination. Similarly, in the CHARISMA study, the combination of aspirin and clopidogrel did not reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, compared with aspirin alone [268]. In patients who have had an acute coronary event within 12 months, or coronary stenting, the combination of clopidogrel and aspirin reduces the risk of new vascular events [325].

Oral anticoagulation
Oral anticoagulation after non-cardiac ischaemic stroke is not superior to aspirin, but causes more bleeding [326–328]. Oral anticoagulation (INR 2.0–3.0) reduces the risk of recurrent stroke in patients with non-valvular AF (whether of permanent, chronic, or paroxysmal type) [329] and most other cardiac sources of emboli. Anticoagulation should be taken long term, or for at least 3 months after cardioembolic stroke due to MI [330]. There is a controversial discussion about the optimal time point to start oral anticoagulation. After TIA or minor stroke one could start immediately, but after major stroke with significant infarction on neuroimaging (e.g. above a third of the MCA territory) one should wait for some (e.g. 4) weeks. However, this decision has to be individualized.

In patients with AF and stable coronary disease, aspirin should not be added to oral anticoagulation [331]. Anticoagulation may be beneficial in patients with aortic atheroma [332], fusiform aneurysms of the basilar artery [333], or cervical dissection [334]. The ongoing ARCH trial is comparing the combination of clopidogrel plus aspirin with oral anticoagulation in secondary prevention of patients with atherosclerotic plaques in the aortic arch.

Recurrent vascular event on antiplatelet therapy
The treatment of patients who have a recurrent vascular event on antiplatelet therapy remains unclear. Alternative causes of stroke should be sought and consistent risk-factor management is mandatory especially in those patients. Alternative treatment strategies may be considered: leave unchanged, change to another antiplatelet agent, add another antiplatelet agent, or use oral anticoagulation.

Surgery and angioplasty

Recommendations
- CEA is recommended for patients with 70–99% stenosis (Class I, Level A). CEA should only be performed in centres with a perioperative complication rate (all strokes and death) of less than 6% (Class I, Level A).
- It is recommended that CEA be performed as soon as possible after the last ischaemic event, ideally within 2 weeks (Class II, Level B).
- It is recommended that CEA may be indicated for certain patients with stenosis of 50–69%; males with very recent hemispheric symptoms are most likely to benefit (Class III, Level C). CEA for stenosis of 50–69% should only be performed in centres with a perioperative complication rate (all stroke and death) of less than 3% (Class I, Level A).
- CEA is not recommended for patients with stenosis of less than 50% (Class I, Level A).
- It is recommended that patients remain on antiplatelet therapy both before and after surgery (Class I, Level A).
- Carotid percutaneous transluminal angioplasty and/or stenting (CAS) is only recommended in selected patients (Class I, Level A). It should be restricted to the following subgroups of patients with severe symptomatic carotid artery stenosis: those with contraindications to CEA, stenosis at a surgically inaccessible site, re-stenosis after earlier CEA, and post-radiation stenosis (Class IV, GCP). Patients should receive a combination of clopidogrel and aspirin immediately before and for at least 1 month after stenting (Class IV, GCP).
- It is recommended that endovascular treatment may be considered in patients with symptomatic intracranial stenosis (Class IV, GPC).

Carotid endarterectomy
The grading of stenosis should be performed according to the NASCET criteria. Although ECST (European Carotid Surgery Trialists) and NASCET use different methods of measurement, it is possible to convert the percentage stenosis derived by one method to the other [335]. CEA reduces the risk of recurrent disabling stroke or death (RR 0.52) in patients with severe (70–99%) ipsilateral internal carotid artery stenosis [279, 336, 337]. Patients with less severe ipsilateral carotid stenosis (50–69%) may also benefit [337]. Surgery is potentially harmful in patients with mild or moderate degrees of stenosis (<50%) [337]. CEA should be performed as soon as possible (ideally within 2 weeks) after the last cerebrovascular event [338].
Surgical procedure is important in preventing stroke; carotid patch angioplasty may reduce the risk of perioperative arterial occlusion and restenosis [339].

Older patients (>75 years) without organ failure or serious cardiac dysfunction benefit from CEA [338]. Women with severe (>70%) symptomatic stenosis should undergo CEA, whereas women with more moderate stenosis should be treated medically [340]. Patients with amaurosis fugax, severe stenosis, and a high-risk profile should be considered for CEA; those with amaurosis fugax and few risk factors do better with medical treatment. Patients with mild-to-moderate intracranial stenosis and severe extracranial stenosis should be considered for CEA.

The benefit from CEA is less in patients with lacunar stroke [341]. Patients with leukoaraiosis carry an increased perioperative risk [342]. Occlusion of the contralateral ICA is not a contraindication to CEA but carries a higher perioperative risk. The benefit from endarterectomy is marginal in patients with carotid near-occlusion.

**Carotid angioplasty and stenting**

Several trials have compared CAS and CEA in secondary stroke prevention (table 9.9) [343–346]. However, the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial included more than 70% asymptomatic patients, and therefore should not be used for decisions about secondary prevention [345]. In CAVATAS (Carotid and Vertebral Artery Transluminal Angioplasty Study) the majority of the patients in the endovascular group underwent angioplasty, and only 26% were treated with a stent [346]. The two most recent studies revealed different results. SPACE (Stent-protected Angioplasty versus Carotid Endarterectomy in symptomatic patients) marginally failed to prove the non-inferiority of CAS compared to CEA; for the endpoint ipsilateral stroke or death up to day 30, the event rates after 1,200 patients were 6.8% for CAS and 6.3% for CEA-patients (absolute difference 0.5%; 95% CI −1.9% to +2.9%; \( p = 0.09 \)) [344]. The French EVA3S (Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis) trial was stopped prematurely after the inclusion of 527 patients because of safety concerns and lack of efficacy. The RR of any stroke or death after CAS, compared with CEA, was 2.5 (95% CI 1.2–5.1) [343]. An updated meta-analysis of these studies revealed a significantly higher risk of any stroke and death within 30 days after CAS, compared with CEA (OR 1.41; 95% CI 1.07–1.87; \( p = 0.016 \)). However, significant heterogeneity was found in this analysis (\( p = 0.035 \)) [347]. After the periprocedural period, few ipsilateral strokes occurred with either procedure (table 9.9).

**Intracranial and vertebral artery occlusive disease**

**Extracranial-intracranial anastomosis**

Anastomosis between the superficial temporal and middle cerebral arteries is not beneficial in preventing stroke in patients with MCA or ICA stenosis or occlusion [348].

### Table 9.9 Risk of stroke or death from large-scale randomized trials comparing endovascular and surgical treatment in patients with severe carotid artery stenosis.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Any stroke or death at 30 days</th>
<th>Disabling stroke or death at 30 days</th>
<th>Ipsilateral stroke after 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CAS n (%)</td>
<td>CEA n (%)</td>
<td>CAS n (%)</td>
</tr>
<tr>
<td>CAVATAS [346]</td>
<td>25 (10.0)</td>
<td>25 (9.9)</td>
<td>16 (6.4)</td>
</tr>
<tr>
<td>SAPPHIRE [345]</td>
<td>8 (4.8)</td>
<td>9 (5.4)</td>
<td>unk</td>
</tr>
<tr>
<td>SPACE [344, 585]</td>
<td>46 (7.7)</td>
<td>38 (6.5)</td>
<td>29 (4.8)</td>
</tr>
<tr>
<td>EVA3S [343]</td>
<td>25 (9.6)</td>
<td>10 (3.9)</td>
<td>9 (3.4)</td>
</tr>
</tbody>
</table>

Intention-to-treat data; unk: unknown.

*Follow-up duration 1.95 years in mean; *up to 6 months.
Stenting of intracranial or vertebral artery stenoses
Patients with symptomatic intracranial stenoses of ≥50% are at high risk of recurrent strokes, both in the anterior and posterior circulation (12% after 1 year and 15% after 2 years in the territory of the stenosed artery) [317, 349]. Severe stenoses (≥70%) carry a higher risk than moderate stenoses (50% to <70%) [349]. After stenting, recurrent strokes are reported in about 5–7% of patients with moderate or severe stenoses after 1 year, and in around 8% after 2 years [350, 351]. However, the incidence of complications after either angioplasty or stenting may be up to 6% [352-354]. No randomized controlled trials have evaluated angioplasty, stenting, or both for intracranial stenosis. Several non-randomized trials have shown feasibility and acceptable safety of intracranial stenting, but the risk of restenosis remains high [354, 355]. Also stenting of the extracranial segments of the vertebral artery is technically feasible with a moderate peri-procedural risk as demonstrated in the SSILVIA trial for example; but especially at the origin there is a particular high rate of restenoses [355].

General stroke treatment

**Recommendations**

- Interim monitoring of neurological status, pulse, blood pressure, temperature, and oxygen saturation is recommended for 72 h in patients with significant persisting neurological deficits (Class IV, GCP).
- It is recommended that oxygen should be administered if the oxygen saturation falls below 95% (Class IV, GCP).
- Regular monitoring of fluid balance and electrolytes is recommended in patients with severe stroke or swallowing problems (Class IV, GCP).
- Normal saline (0.9%) is recommended for fluid replacement during the first 24 h after stroke (Class IV, GCP).
- Routine blood pressure lowering is not recommended following acute stroke (Class IV, GCP).
- Cautious blood pressure lowering is recommended in patients with extremely high blood pressures (>220/120 mmHg) on repeated measurements, or with severe cardiac failure, aortic dissection, or hypertensive encephalopathy (Class IV, GCP).
- It is recommended that abrupt blood pressure lowering be avoided (Class II, Level C).

- It is recommended that low blood pressure secondary to hypovolaemia or associated with neurological deterioration in acute stroke should be treated with volume expanders (Class IV, GCP).
- Monitoring serum glucose levels is recommended (Class IV, GCP).
- Treatment of serum glucose levels >180 mg/dl (>10 mmol/l) with insulin titration is recommended (Class IV, GCP).
- It is recommended that severe hypoglycaemia (<50 mg/dl [<2.8 mmol/l]) should be treated with i.v. dextrose or infusion of 10–20% glucose (Class IV, GCP points).
- It is recommended that the presence of pyrexia (temperature >37.5°C) should prompt a search for concurrent infection (Class IV, GCP).
- Treatment of pyrexia (temperature >37.5°C) with paracetamol and fanning is recommended (Class III, Level C).
- Antibiotic prophylaxis is not recommended in immunocompetent patients (Class II, Level B).

The term ‘general treatment’ refers to treatment strategies aimed at stabilizing the critically ill patient in order to control systemic problems that may impair stroke recovery; the management of such problems is a central part of stroke treatment [2, 105]. General treatment includes respiratory and cardiac care, fluid and metabolic management, blood pressure control, the prevention and treatment of conditions such as seizures, venous thromboembolism, dysphagia, aspiration pneumonia, other infections, or pressure ulceration, and occasionally management of elevated intracranial pressure. However, many aspects of general stroke treatment have not been adequately assessed in randomized clinical trials.

It is common practice to actively manage neurological status and vital physiological functions such as blood pressure, pulse, oxygen saturation, blood glucose, and temperature. Neurological status can be monitored using validated neurological scales such as the NIH Stroke Scale [103] or the Scandinavian Stroke Scale [356]. There is little direct evidence from randomized clinical trials to indicate how intensively monitoring should be carried out, but in stroke unit trials [118] it was common practice to have a minimum of 4-hourly observations for the first 72 h after stroke. Clinical trials using continuous telemetry [357, 358] suggest there may be some benefit from more intensive continuous monitoring in terms of improved detection of complications and reduced length.
of stay, but clinical outcomes are inconclusive. In practice, more intensive monitoring is often provided for subgroups of patients, such as those with reduced consciousness, progressing neurological deficits, or a history of cardiorespiratory disease. Close monitoring is also required for the first 24 h after thrombolysis. More invasive monitoring procedures, such as central venous catheters or intracranial pressure monitoring, are used only in highly selected patient groups.

**Pulmonary function and airway protection**
Normal respiratory function with adequate blood oxygenation is believed to be important in the acute stroke period to preserve ischaemic brain tissue. However, there is no convincing evidence that routine provision of oxygen at low flow rates to all acute stroke patients is effective [359]. Identification and treatment of hypoxia is believed to be important in individuals with extensive brainstem or hemispheric stroke, seizure activity, or complications such as pneumonia, cardiac failure, pulmonary embolism, or exacerbation of chronic obstructive pulmonary disease (COPD). Blood oxygenation is usually improved by the administration of 2–4 litres of oxygen via a nasal tube. Ventilation may be necessary in patients with severely compromised respiratory function. However, before ventilation is performed the general prognosis, coexisting medical conditions, and the presumed wishes of the patient need to be considered.

**Cardiac care**
Cardiac arrhythmias, particularly AF, are relatively common after stroke, and heart failure, myocardial infarction, and sudden death are also recognized complications [360, 361]. A significant minority of stroke patients show raised blood troponin levels indicative of cardiac damage [362]. Every stroke patient should have an initial ECG. Cardiac monitoring should be conducted to screen for AF. Optimizing cardiac output with maintenance of high normal blood pressure and a normal heart rate is a standard component of stroke management. The use of inotropic agents is not routine practice, but fluid replacement therapy is commonly used to correct hypovolaemia. Increases in cardiac output may increase cerebral perfusion. Restoration of normal cardiac rhythm using drugs, cardioversion, or pacemaker support may occasionally be required.

**Fluid replacement therapy**
Many stroke patients are dehydrated on admission to hospital, and this is associated with a poor outcome [363]. Although clinical trial evidence is limited, delivery of i.v. fluids is commonly considered part of general management of acute stroke, particularly in patients at risk of dehydration due to reduced consciousness or impaired swallowing. Experience in the management of hyperglycaemia supports the avoidance of dextrose in the early post-stroke phase [364]. More specialist fluid replacement therapy with haemodilution has not been shown to improve stroke outcomes [365].

**Blood pressure management**
Blood pressure monitoring and treatment is a controversial area in stroke management. Patients with the highest and lowest levels of blood pressure in the first 24 h after stroke are more likely to have early neurological decline and poorer outcomes [366]. A low or low-normal blood pressure at stroke onset is unusual [367], and may be the result of a large cerebral infarct, cardiac failure, ischaemia, hypovolaemia, or sepsis. Blood pressure can usually be raised by adequate rehydration with crystalloid (saline) solutions; patients with low cardiac output may occasionally need inotropic support. However, clinical trials of actively elevating a low blood pressure in acute stroke have yielded inconclusive results.

A systematic review covering a variety of blood pressure altering agents has not provided any convincing evidence that active management of blood pressure after acute stroke influences patient outcomes [368]. Small studies looking at surrogate markers of cerebral blood flow such as SPECT have indicated that neither perindopril nor losartan lower cerebral blood flow when given within 2–7 days of stroke onset [369]. Several ongoing trials are examining whether blood pressure should be lowered after acute stroke, and whether antihypertensive therapy should be continued or stopped in the first few days after stroke [370, 371]. In the absence of reliable evidence from clinical trials, many clinicians have developed protocols for the management of extremely high blood pressure. In some centres it is common practice to begin cautious blood pressure reduction when levels exceed 220 mmHg systolic and 120 mmHg diastolic. However, in many centres blood pressure reduction is only considered in the presence of severe cardiac insufficiency, acute renal failure, aortic arch dissection, or
malignant hypertension. In patients undergoing thrombolysis it is common practice to avoid systolic blood pressures above 185 mmHg.

The use of sublingual nifedipine should be avoided because of the risk of an abrupt decrease in blood pressure [372]. Intravenous labetalol or urapadil are frequently used in North America. Sodium nitroprusside is sometimes recommended.

**Specific treatment**

**Blood glucose management**

Hyperglycaemia occurs in up to 60% of stroke patients without known diabetes [373, 374]. Hyperglycaemia after acute stroke is associated with larger infarct volumes and cortical involvement, and with poor functional outcome [375-377]. There is limited evidence as to whether active reduction of glucose in acute ischaemic stroke improves patient outcomes. The largest randomized trial of blood glucose lowering by glucose potassium insulin infusion [364], compared with standard i.v. saline infusion, found no difference in mortality or functional outcomes in patients with mild-to-moderate blood glucose elevations (median 137 mg/dl [7.6 mmol/l]). This regime was labour-intensive and associated with episodes of hypoglycaemia. At present the routine use of insulin infusion regimes in patients with moderate hyperglycaemia cannot be recommended. However, it is common practice in stroke units to reduce blood glucose levels exceeding 180 mg/dl (10 mmol/l) [118]. The use of i.v. saline and avoidance of glucose solutions in the first 24 h after stroke is common practice, and appears to reduce blood glucose levels [364].

Hypoglycaemia (<50 mg/dl [2.8 mmol/l]) may mimic an acute ischaemic infarction, and should be treated by i.v. dextrose bolus or infusion of 10–20% glucose [378].

**Body temperature management**

In experimental stroke, hyperthermia is associated with increased infarct size and poor outcome [379]. Raised temperature can be centrally driven or a result of concurrent infection, and is associated with poorer clinical outcomes [380-382]. A raised body temperature should prompt a search for infection and treatment where appropriate. Studies with antipyretic medication have been inconclusive, but treatment of raised body temperature (>37.5°C) with paracetamol is common practice in stroke patients.

**Thrombolytic therapy**

**Intravenous tissue plasminogen activator**

Thrombolytic therapy with rtPA (0.9 mg/kg body weight, maximum dose 90 mg) given within 3 h after stroke onset
significantly improves outcome in patients with acute ischaemic stroke [125]: the NNT to achieve a favourable clinical outcome after 3 months is 7. By contrast, the ECASS (European Cooperative Acute Stroke Study) and ECASS II studies did not show statistically significant superiority of rtPA for the primary endpoints when treatment was given within 6 h [383, 384]. Trials with rtPA, involving a total of 2,889 patients, have shown a significant reduction in the number of patients with death or dependency (OR 0.83; 95% CI 0.73–0.94) [385]. A pooled analysis of individual data of rtPA trials showed that, even within a 3-h window, earlier treatment results in a better outcome (0–90 min: OR 2.11; 95% CI 1.33 to 3.55; 90–180 min: OR 1.69; 95% CI 1.09 to 2.62) [386]. This analysis suggested a benefit up to 4.5 h.

The recently published trial European Cooperative Acute Stroke Study III (ECASS III) has shown that i.v. alteplase administered between 3 and 4.5 h (median 3 h 59 min) after the onset of symptoms significantly improves clinical outcomes in patients with acute ischaemic stroke compared to placebo [387, 388]; the absolute improvement was 7.2% and the adjusted OR of favourable outcome (mRS 0–1) was 1.42, 1.02–1.98. Mortality did not differ significantly (7.7% versus 8.4%), but alteplase increased the risk of SICH (2.4% versus 0.2%). Treatment benefit is time-dependent. The number needed to treat to get one more favourable outcome drops from 2 during the first 90 min through 7 within 3 h and towards 14 between 3 and 4.5 h [387, 388].

The SITS investigators compared 664 patients with ischaemic stroke treated between 3 and 4.5 h otherwise compliant with the European summary of the product characteristics criteria with 11,865 patients treated within 3 h [389].

In the 3–4.5-h cohort, treatment was started on average 55 min later after symptom onset. There were no significant differences between the 3–4.5-h cohort and the 3-h cohort for any outcome measures, confirming that alteplase remains safe when given between 3 and 4.5 h after the onset of symptoms in ischaemic stroke patients who otherwise fulfil the European summary of product characteristics criteria [389] (modified January 2009).

The NINDS (National Institute of Neurological Disorders and Stroke) Study showed that the extent of early ischaemic changes (using the ASPECT score) had no effect on treatment response within the 3-h time window [387]. However, European regulatory agencies do not advocate rtPA treatment in patients with severe stroke (NIHSSS ≥25), extended early ischaemic changes on CT scan, or age above 80 years (unlike the US labelling). Nevertheless, observational studies suggest that rtPA given within 3 h of stroke onset is safe and effective in patients over 80 years of age [390–392], but more randomized data are pending. The effect of gender on the response to rtPA is uncertain [393].

Thrombolytic therapy appears to be safe and effective across various types of hospitals, if the diagnosis is established by a physician with stroke expertise and brain CT is assessed by an experienced physician [394–396]. Whenever possible, the risks and benefits of rtPA should be discussed with the patient and family before treatment is initiated.

Blood pressure must be below 185/110 mmHg before, and for the first 24 h after, thrombolysis. Management of high blood pressure is required [125]. Protocol violations are associated with higher mortality rates [397, 398].

Continuous transcranial ultrasound was associated with an increased rate of early recanalization after rtPA in a small randomized trial [399]; this effect may be facilitated by the administration of microbubbles [400]. However, a randomized clinical trial has recently been stopped for undisclosed reasons.

Intravenous rtPA may be of benefit also for acute ischaemic stroke beyond 3 h after onset, but is not recommended in clinical routine. The use of multimodal imaging criteria may be useful for patient selection. Several large observational studies suggest improved safety and possibly improved efficacy in patients treated with i.v. rtPA beyond 3 h based on advanced imaging findings [130, 159, 401, 402]. However, available data on mismatch, as defined by multimodal MRI or CT, are too limited to guide thrombolysis in routine practice (see also the section on imaging) [152].

Patients with seizures at stroke onset have been excluded from thrombolytic trials because of potential confusion with post-ictal Todd’s phenomena. Case series have suggested that thrombolysis may be used in such patients when there is evidence for new ischaemic stroke [390].

Post hoc analyses have identified the following potential factors associated with increased risk of intracerebral bleeding complications after rtPA use [403]:

- elevated serum glucose
- history of diabetes
• baseline symptom severity
• advanced age
• increased time to treatment
• previous aspirin use
• history of congestive heart failure
• low plasminogen activator inhibitor activity
• NINDS protocol violations.
However, none of these factors reversed the overall benefit of rtPA.

Other intravenous thrombolytics
Intravenous streptokinase was associated with an unacceptable risk of haemorrhage and death [404, 405]. Intravenous desmoteplase administered 3 to 9 h after acute ischaemic stroke in patients selected on the basis of perfusion/diffusion mismatch was associated with a higher rate of reperfusion and better clinical outcome, compared with placebo, in two small randomized clinical trials (RCTs) [406, 407]. These findings were not confirmed in the phase III DIAS (Desmoteplase in Acute Ischemic Stroke)-II study, but this agent will be evaluated further.

Intra-arterial and combined (IV + IA) thrombolysis
Intra-arterial thrombolytic treatment of proximal MCA occlusion using pro-urokinase (PUK) within 6 h was significantly associated with better outcome in the PROACT II (Pro-urokinase for Acute Ischemic Stroke) trial [153]. Additional smaller RCTs with PUK (PROACT I) or urokinase (MELT) and a meta-analysis of PROACT I, PROACT II, and MELT indicate a benefit of intra-arterial thrombolytic therapy in patients with proximal MCA occlusions [408]. Pro-urokinase is not available and intra-arterial thrombolysis with tPA is not substantiated by RCTs, but observational data and non-randomised comparisons are available [154, 409].

A randomized trial comparing standard i.v. rtPA with a combined intravenous and intra-arterial approach (IMS3) has started [410].

Intra-arterial treatment of acute basilar occlusion with urokinase or rtPA has been available for more than 20 years, but has not been tested in an adequately powered RCT [411], although encouraging results have been obtained in observational studies [412, 413]. A systematic analysis found no significant differences between intravenous or intra-arterial thrombolysis for basilar occlusion [414].

Intra-arterial recanalization devices
The MERCI (Mechanical Embolus Removal in Cerebral Embolism) trial evaluated a device that removed the thrombus from an intracranial artery. Recanalization was achieved in 48% (68/141) of patients in whom the device was deployed within 8 h of the onset of stroke symptoms [415]. No RCTs with outcome data are available for any recanalization devices.

Antiplatelet therapy
The results of two large randomized, non-blinded, intervention studies indicate that aspirin is safe and effective when started within 48 h after stroke [416, 417]. In absolute terms, 13 more patients were alive and independent at the end of follow-up for every 1000 patients treated. Furthermore, treatment increased the odds of making a complete recovery from the stroke (OR 1.06; 95% CI 1.01–1.11): 10 more patients made a complete recovery for every 1000 patients treated. Antiplatelet therapy was associated with a small but definite excess of two symptomatic intracranial haemorrhages for every 1000 patients treated, but this was more than offset by a reduction of seven recurrent ischaemic strokes and about one pulmonary embolism for every 1000 patients treated.

A randomized, double-blind, placebo-controlled trial showed that aspirin (325 mg), given once daily for 5 consecutive days and starting within 48 h of stroke onset, did not significantly reduce stroke progression, compared with placebo (RR 0.95; 95% CI 0.62–1.45) in patients with incomplete paresis [418].

The use of clopidogrel, dipyridamole, or combinations of oral antiplatelet agents in acute ischaemic stroke has not been evaluated.

In a double-blind phase II, the glycoprotein-IIb-IIIa inhibitor abciximab produced a non-significant shift in favourable outcomes, as measured by modified Rankin scores (mRS) at 3 months, compared with placebo (OR 1.20; 95% CI 0.84–1.70) [419]. A phase III study evaluating the safety and efficacy of abciximab was terminated prematurely after 808 patients had been enrolled because of an increased rate of symptomatic or fatal intracranial bleeding with abciximab compared to placebo (5.5% versus 0.5%; p = 0.002). This trial also did not demon-
strate an improvement in outcomes with abciximab [420].

**Early anticoagulation**

Subcutaneous unfractionated heparin (UFH) at low or moderate doses [415], nadroparin [421, 422], certoparin [423], tinzaparin [424], dalteparin [425], and i.v. danaparoid [426] have failed to show an overall benefit of anticoagulation when initiated within 24 to 48 h from stroke onset. Improvements in outcome or reductions in stroke recurrence rates were mostly counterbalanced by an increased number of haemorrhagic complications. In a meta-analysis of 22 trials, anticoagulant therapy was associated with about nine fewer recurrent ischaemic strokes per 1000 patients treated (OR 0.76; 95% CI 0.65–0.88), and with about nine more symptomatic intracranial haemorrhages per 1,000 (OR 2.52; 95% CI 1.92–3.30) [427]. However, the quality of the trials varied considerably. The anticoagulants tested were standard UFH, low molecular weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors.

Few clinical trials have assessed the risk-benefit ratio of very early administration of UFH in acute ischaemic stroke. In one study, patients with nonlacunar stroke anticoagulated within 3 h had more self-independence (38.9% versus 28.6%; \( p = 0.025 \)), fewer deaths (16.8% versus 21.9%; \( p = 0.189 \)), and more symptomatic brain haemorrhages (6.2% versus 1.4%; \( p = 0.008 \)) [428]. In the RAPID (Rapid Anticoagulation Prevents Ischemic Damage) trial, patients allocated UFH had fewer early recurrent strokes and a similar incidence of serious haemorrhagic events, compared with those receiving aspirin [429]. In the UFH group, ischaemic or haemorrhagic worsening was associated with inadequate plasma levels of UFH. In view of these findings, the value of UFH administered shortly after symptom onset is still debated [430, 431]. RCTs have not identified a net benefit of heparin for any stroke subtype. A meta-analysis restricted to patients with acute cardioembolic stroke showed that anticoagulants given within 48 h of clinical onset were associated with a non-significant reduction in recurrence of ischaemic stroke, but no substantial reduction in death or disability [432]. Despite this lack of evidence, some experts recommend full-dose heparin in selected patients, such as those with cardiac sources of embolism with high risk of re-embolism, arterial dissection, or high-grade arterial stenosis prior to surgery. Contraindications for heparin treatment include large infarcts (e.g. more than 50% of MCA territory), uncontrollable arterial hypertension and advanced microvascular changes in the brain.

**Neuroprotection**

No neuroprotection programme has shown improved outcome on its predefined primary endpoint. Recent RCTs with the free radical trapping agent NXY-059 [433] and magnesium sulphate [434] were negative. A randomized, placebo-controlled, phase III trial of i.v. rtPA followed by antioxidant therapy with uric acid is ongoing, following a safe phase II study [435]. A meta-analysis has suggested a mild benefit with citicoline [436]; a clinical trial with this agent is in progress.

**Brain oedema and elevated intracranial pressure**

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Surgical decompressive therapy within 48 h after symptom onset is recommended in patients up to 60 years of age with evolving malignant MCA infarcts (Class I, Level A).</td>
</tr>
<tr>
<td>• It is recommended that osmotherapy can be used to treat elevated intracranial pressure prior to surgery if this is considered (Class III, Level C).</td>
</tr>
<tr>
<td>• No recommendation can be given regarding hypothermic therapy in patients with space-occupying infarctions (Class IV, GCP).</td>
</tr>
<tr>
<td>• It is recommended that ventriculostomy or surgical decompression be considered for treatment of large cerebellar infarctions that compress the brainstem (Class III, Level C).</td>
</tr>
</tbody>
</table>

Space-occupying brain oedema is a main cause of early deterioration and death in patients with large supratentorial infarcts. Life-threatening brain oedema usually develops between the second and fifth day after stroke onset, but up to a third of patients can have neurological deterioration within 24 h after symptom onset [437, 438].

**Medical therapy**

Medical therapy in patients with large space-occupying infarctions and brain oedema is based mostly on observational data. Basic management includes head positioning at an elevation of up to 30°, avoidance of noxious stimuli, pain relief, appropriate oxygenation, and normalizing body temperature. If intracranial pressure (ICP)
monitoring is available, cerebral perfusion pressure should be kept above 70 mmHg [439]. Intravenous glycerol (4 × 250 ml of 10% glycerol over 30–60 minutes) or mannitol (25–50 g every 3–6 h) is first-line medical treatment if clinical or radiological signs of space-occupying oedema occur [440, 441]. Intravenous hypertonic saline solutions are probably similarly effective [442]. Hypotonic and glucose-containing solutions should be avoided as replacement fluids. Dexamethasone and corticosteroids are not useful [443]. Thiopental given as a bolus can quickly and significantly reduce ICP, and can be used to treat acute crises. Barbiturate treatment requires ICP and electroencephalography (EEG) monitoring and careful haemodynamic monitoring, as a significant blood pressure drop may occur.

Hypothermia
Mild hypothermia (i.e. brain temperature between 32 and 33°C) reduces mortality in patients with severe MCA infarcts, but may cause severe side effects, including recurrent ICP crisis during re-warming [444, 445]. In a small RCT, mild hypothermia (35°C) in addition to decompressive surgery produced a trend towards a better clinical outcome than decompressive surgery alone (p = 0.08) [446].

Decompressive surgery

Malignant MCA infarction
A pooled analysis of 93 patients included in the DECIMAL (decompressive craniectomy in malignant middle cerebral artery infarcts), DESTINY (decompressive surgery for the treatment of malignant infarction of the middle cerebral artery), and HAMLET (hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial) trials showed that, compared with the control group, at 1 year more patients in the decompressive surgery group had a mRS ≤4 or mRS ≤3, and more survived (NNTs 2, 4 and 2 respectively) [447, 448]. There was no increase in the proportion of patients who survived surgery in a vegetative stage (mRS 5). Inclusion criteria for this combined analysis were age 18–60 years, NIHSSS >15, decrease in level of consciousness to a score of 1 or greater on item 1a of the NIHSS, infarct signs on CT of 50% or more of the MCA territory or >145 cm³ on DWI, and inclusion <45 h after onset (surgery <48 h). Follow-up of survival and functional status beyond 1 year is currently ongoing in the DECIMAL and DESTINY studies [448].

A systematic review of 12 observational retrospective studies found age above 50 years to be a predictor of poor outcome. The timing of surgery, side of infarction, clinical signs of herniation before surgery, and involvement of other vascular territories did not significantly affect outcome [449].

Cerebellar infarction
Ventriculostomy and decompressive surgery are considered treatments of choice for space-occupying cerebellar infarctions, although RCTs are lacking. As in space-occupying supratentorial infarction, the operation should be performed before signs of herniation are present. The prognosis among survivors can be very good, even in patients who are comatose before surgery.

Prevention and management of complications

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• It is recommended that infections after stroke should be treated with appropriate antibiotics (Class IV, GCP).</td>
</tr>
<tr>
<td>• Prophylactic administration of antibiotics is not recommended, and levofloxacin can be detrimental in acute stroke patients (Class II, Level B).</td>
</tr>
<tr>
<td>• Early rehydration and graded compression stockings are recommended to reduce the incidence of venous thromboembolism (Class IV, GCP).</td>
</tr>
<tr>
<td>• Early mobilization is recommended to prevent complications such as aspiration pneumonia, DVT, and pressure ulcers (Class IV, GCP).</td>
</tr>
<tr>
<td>• It is recommended that low-dose subcutaneous heparin or low molecular weight heparins should be considered for patients at high risk of DVT or pulmonary embolism (Class I, Level A).</td>
</tr>
<tr>
<td>• Administration of anticonvulsants is recommended to prevent recurrent post-stroke seizures (Class I, Level A). Prophylactic administration of anticonvulsants to patients with recent stroke who have not had seizures is not recommended (Class IV, GCP).</td>
</tr>
<tr>
<td>• An assessment of falls risk is recommended for every stroke patient (Class IV, GCP).</td>
</tr>
<tr>
<td>• Calcium/Vitamin D supplements are recommended in stroke patients at risk of falls (Class II, Level B).</td>
</tr>
<tr>
<td>• Bisphosphonates (alendronate, etidronate, and risedronate) are recommended in women with previous fractures (Class II, Level B).</td>
</tr>
</tbody>
</table>
Aspiration and pneumonia
Bacterial pneumonia is one of the most important complications in stroke patients [450], and is mainly caused by aspiration [451]. Aspiration is frequently found in patients with reduced consciousness and in those with swallowing disturbances. Oral feeding should be withheld until the patient has demonstrated intact swallowing with small amounts of water and intact coughing on command. Nasogastric (NG) or percutaneous enteral gastrostomy (PEG) feeding may prevent aspiration pneumonia, although reflux of liquid feed, hypostasis, diminished cough, and immobilization increase the risk. Frequent changes of the patient’s position in bed and pulmonary physical therapy may prevent aspiration pneumonia. A brain-mediated immunodepressive state contributes to post-stroke infection [452, 453]. Prophylactic administration of levofloxacin (500 mg/100 ml/day for 3 days) is not better than optimal care for the prevention of infection in patients with nonseptic acute stroke and was inversely associated with outcome at day 90 (OR 0.19–0.59) and pulmonary embolism (OR 0.36; 95% CI 0.15–0.87), without an increased risk of intracerebral (OR 1.39; 95% CI 0.53–3.67) or extracerebral hemorrhage (OR 1.44; 95% CI 0.13–16), NNT: 7 and 38 for DVT and pulmonary embolism respectively, while low-dose UFH decreased the thrombosis risk (OR 0.17; 95% CI 0.11–0.26), but had no influence on pulmonary embolism (OR 0.83, 95% CI 0.53–1.31); the risk of ICH was not statistically significantly increased (OR 1.67; 95% CI 0.97–2.87) [456]. Nevertheless, prophylaxis with subcutaneous low-dose heparin (5000 IU twice daily) or low molecular weight heparins is indicated in patients at high risk of DVT or PE (e.g. due to immobilization, obesity, diabetes, previous stroke) [457, 458].

Pressure ulcer
In patients at high risk of developing pressure ulcers, use of support surfaces, frequent repositioning, optimizing nutritional status, and moisturizing sacral skin are appropriate preventive strategies [459]. The skin of the incontinent patient must be kept dry. For patients at particularly high risk, an air-filled or fluid-filled mattress system should be used.

Seizures
Partial or secondary generalized seizures may occur in the acute phase of ischaemic stroke. Standard anti-epileptic drugs should be used based on general principles of seizure management. There is no evidence that primary prophylactic anticonvulsive treatment is beneficial.

Agitation
Agitation and confusion may be a consequence of acute stroke, but may also be due to complications such as fever, volume depletion, or infection. Adequate treatment of the underlying cause must precede any type of sedation or antipsychotic treatment.

Falls
Falls are common (up to 25%) after stroke in the acute setting [460], during inpatient rehabilitation [461], and in the long term [462]. Likely risk factors for falls in stroke survivors [463] include cognitive impairment, depression, polypharmacy, and sensory impairment [464, 465]. A multidisciplinary prevention package that focuses on personal and environmental factors has been found to be successful in general rehabilitation settings.
There is a 5% incidence of serious injury [460], including hip fractures (which are four-fold more common than in age-matched controls [468]), which is associated with poor outcome [469]. Exercise [470], calcium supplements [471], and bisphosphonates [472] improve bone strength and decrease fracture rates in stroke patients. Hip protectors can reduce the incidence of fracture for high-risk groups in institutional care, but evidence is less convincing for their use in a community setting [473].

**Urinary tract infections and incontinence**

Intermittent catheterization has not been shown to reduce the risk of infection. Once urinary infection is diagnosed, appropriate antibiotics should be chosen; to avoid bacterial resistance developing, prophylactic antibiotics are best avoided.

Urinary incontinence is common after stroke, particularly in older, more disabled, and cognitively impaired patients [476]. Recent estimates suggest a prevalence of 40–60% in an acute stroke population, of whom 25% are still incontinent at discharge and 15% remain incontinent at one year [477]. Urinary incontinence is a strong predictor of poor functional outcome, even after correcting for age and functional status [478]. However, data from the available trials are insufficient to guide continence care of adults after stroke [475, 479]. However, there is suggestive evidence that professional input through structured assessment and management of care and specialist continence nursing may reduce urinary incontinence and related symptoms after stroke. Structured assessment and physical management have been shown to improve continence rates in both inpatients and outpatients [475, 477]. However, trials of interventions are insufficient in number and quality to make any recommendations [479].

**Dysphagia and feeding**

Oropharyngeal dysphagia occurs in up to 50% of patients with unilateral hemiplegic stroke [480]. The prevalence of dysphagia is highest in the acute stages of stroke, and declines to around 15% at 3 months [481]. Dysphagia is associated with a higher incidence of medical complications and increased overall mortality [480].

Withholding or limiting oral intake can worsen the catabolic state that may be associated with an acute illness such as stroke. Estimates of the incidence of malnutrition vary from 7 to 15% at admission [482, 483] and 22 to 35% at 2 weeks [484]. Among patients requiring prolonged rehabilitation, the prevalence of malnutrition may reach 50% [485]. Malnutrition predicts a poor functional outcome [486] and increased mortality [487, 488]. However, routine supplementation for all acute stroke patients did not improve outcomes or reduce complications [489]. There are no adequately powered trials of targeting supplementation to stroke patients at high risk of malnutrition.

For patients with continuing dysphagia, options for enteral nutrition include NG or PEG feeding. A trial of early (median 48 h post-stroke) versus delayed (1 week) NG feeding found no significant benefit of early feeding, although there was a trend to fewer deaths in the early NG group [489]. In a related trial examining PEG and NG feeding within 30 days, PEG feeding was no better than NG and in fact was potentially harmful [489]. PEG feeding has also been studied in longer-term dysphagia. Two trials comparing PEG and NG feeding found a trend towards improved nutrition with PEG feeding that did not reach statistical significance [490, 491]. Studies that have addressed quality of life found it was not improved by PEG feeding [492, 493].

**Rehabilitation**

Even with optimal stroke unit care including thrombolysis, fewer than one-third of patients recover fully from stroke [388]. Rehabilitation aims to enable people with disabilities to reach and maintain optimal physical, intellectual, psychological, and/or social function [494]. Goals of rehabilitation can shift from initial input to minimize impairment to more complex interventions designed to encourage active participation.

**Setting for rehabilitation**

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Admission to a stroke unit is recommended for acute stroke patients to receive co-ordinated multidisciplinary rehabilitation (Class I, Level A).</td>
</tr>
<tr>
<td>• Early initiation of rehabilitation is recommended (Class III, Level C).</td>
</tr>
</tbody>
</table>
A key characteristic of stroke units is rehabilitation delivered by a specialized multidisciplinary team [495]. The Stroke Unit Trialists’ Collaboration [61] has shown improved survival and functional outcomes for patients treated in a dedicated stroke ward, and there are also long-term functional benefits of dedicated stroke unit care; follow-up at 5 and 10 years has revealed persisting efficacy compared with controls [496, 497]. The financial and social implications of prolonged hospitalization have prompted increasing interest in services to facilitate early return to the community. A multidisciplinary early supported discharge team with stroke expertise, comprising (at least) nursing, physiotherapy, and occupational therapy, can significantly reduce bed days for selected stroke patients [498] who have mild or moderate impairment at baseline [499]. However, specialist discharge services are required; mortality was substantially increased when patients were discharged early with only generic community support [500].

A meta-analysis showed that continued rehabilitation after discharge during the first year after stroke reduces the risk of deterioration in function and improves activities of daily living [501]. The interventions included occupational therapy, physiotherapy, and multidisciplinary teams, and therefore no definitive statement can be made concerning the optimal mode of service delivery.

**Timing, duration and intensity of rehabilitation**

The optimal timing of rehabilitation is unclear. Proponents of early therapy cite evidence from functional neuroimaging [502] and animal studies [503, 504] that define the peri-infarct period as the crucial time to begin rehabilitation. Early initiation of rehabilitation is a key component of stroke unit care [61] but there is a lack of consensus on the definition of ‘early therapy’. Trials comparing ‘early’ and ‘late’ initiation of rehabilitation have reported improved prognosis if therapy is started within 20–30 days [505, 506]. Many of the immediate complications of stroke (DVT, skin breakdown, contracture formation, constipation, and hypostatic pneumonia) are related to immobility [507], and hence mobilization is a fundamental component of early rehabilitation. The optimal timing of first mobilization is unclear, but mobilization within the first few days appears to be well tolerated [508]. Preliminary results from the ongoing AVERT study of rehabilitation within 24 h suggest that immediate physical therapy is well tolerated with no increase in adverse events [509].

There are few studies of rehabilitation beyond a year after the acute event, and data are inconclusive to make a recommendation on rehabilitation in this phase [510].

Greater intensity of rehabilitation, especially time spent working on activities of daily living (ADL), is associated with improved functional outcomes [511, 512]. A systematic review of rehabilitation therapies for improving arm function also suggests a dose–response relationship, although heterogeneity of included studies precluded a formal measure of effect size [513]. Greatest benefits were observed in studies of lower limb exercises and general ADL training.

Organisation and ‘quality’ of care may be more important than absolute hours of therapy [514]. In a comparison between a dedicated stroke multidisciplinary team and usual ward-based rehabilitation, the dedicated team achieved better outcomes with significantly fewer hours of therapy [515].

### Elements of rehabilitation

**Recommendations**

- It is recommended that early discharge from stroke unit care is possible in medically stable patients with mild or moderate impairment providing that rehabilitation is delivered in the community by a multidisciplinary team with stroke expertise (Class I, Level A).
- It is recommended to continue rehabilitation after discharge during the first year after stroke (Class II, Level A).
- It is recommended to increase the duration and intensity of rehabilitation (Class II, Level B).
aerobic training can improve exercise capacity in individuals with mild to moderate motor deficit post-stroke [470].

Constraint-induced movement therapy involves intensive task-orientated exercise of the paretic limb, with restraint of the non-paretic limb. The EXCITE study reported positive results for this method 3–9 months after stroke in a group of medically stable stroke survivors, with some arm movement benefit persisting at 1 year [524].

Occupational therapy
A systematic review of nine trials comparing occupational therapy (OT)-based ADL therapy with usual care reported improved functional outcomes in the active intervention group [525]. The data do not justify conclusions on the optimal mode of OT delivery.

A meta-analysis of community-based OT trials found improved performance on ADL measures. The greatest effects were seen in older patients and with the use of targeted interventions [526]. Specific leisure-based OT therapies did not translate into improved ADL. A trial of providing OT intervention to care home residents post-stroke found less functional deterioration in the active intervention group [527]. No controlled trial data describe the effectiveness of occupational therapy beyond 1 year after stroke.

Speech and language therapy
Speech and language therapy (SLT) may optimize safe swallowing, and may assist communication. Two trials of formal SLT input for dysphagia found no significant difference to usual care [528]. A study comparing simple written instruction to graded levels of speech and language intervention for dysphagia found no difference in outcomes between the groups [529].

Aphasia and dysarthria are common symptoms after stroke, and impact on quality of life [530]. A systematic review of SLT for dysarthria in non-progressive brain damage (stroke and head injury) found no good-quality evidence for benefit [531]. Similarly, a systematic review of SLT for aphasia [532] reported insufficient good-quality evidence to recommend formal or informal interventions. The studies included in this review were community-based and had an average time to therapy of 3 months; they offer little to inform acute ward-based rehabilitation. Two related meta-analyses of studies with...
weaker design concluded that improvement in speech is greater if SLT is initiated early [533, 534]. Limited evidence supports the possible use of modified constraint-induced therapy for patients with aphasia [535, 536].

**Stroke liaison and information provision**

A recent systematic review comparing dedicated stroke liaison to usual care found no evidence of improvement in ADL, subjective health status, or carers' health [537]. On subgroup analysis, success of a stroke liaison service was predicted by younger age, less severe deficit, and an emphasis on education within the service.

Inadequate provision of information is predictive of poor quality of life in stroke patients and their families [538]. There is some evidence that combining information with educational sessions improves knowledge and is more effective than providing information alone [539].

As the patient progresses from hospital-based rehabilitation to the community, involvement of carers in rehabilitation becomes increasingly important. Formal training of caregivers in delivery of care reduces personal costs and improves quality of life [540].

**Other groups**

Depending on patient-specific goals, input from various other therapists may be appropriate. Such groups include dieticians, orthoptists, and social workers. Although there has been limited formal research in this area, some authors have argued that dedicated staffing creates an 'enriched environment' that encourages practice in rehabilitation activities outside periods of formal therapy [541].

**Cognitive deficits**

Cognitive deficits are common following stroke and impact on quality of life. At present, there is no evidence for the efficacy of specific memory rehabilitation [542]. Cognitive training for attention deficit has not resulted in meaningful clinical improvement in ADL measures [543]. Training for spatial neglect has improved impairment measures, but an effect on ADL performance has not been demonstrated [544]. A few studies have assessed rehabilitation training strategies in visual inattention and apraxia; no specific conclusions can be drawn [545].

**Sexuality**

Sexuality can suffer after a stroke. Underlying physical limitations and comorbid vascular disease may be compounded by side effects of medications [546]. It may be desirable to discuss issues of sexuality and intimacy with patients [547]. Provision of support and information is important; many patients wrongly fear that resuming an active sex life may result in further stroke [548].

**Complications affecting rehabilitation**

Rehabilitation can be compromised by complications, which may be strong predictors of poor functional outcome and mortality. Common complications during inpatient rehabilitation include depression, shoulder pain, falls, urinary disturbances, and aspiration pneumonia [549]. Some of these are discussed under 'Prevention of complications'.

**Post-stroke depression**

Post-stroke depression is associated with poor rehabilitation results and ultimately poor outcome [550, 551]. In clinical practice, only a minority of depressed patients are diagnosed and even fewer are treated [552]. Depression has been reported in up to 33% of stroke survivors, compared with 13% of age- and sex-matched controls [553], but reliable estimates of the incidence and prevalence of depression in a stroke cohort are limited [551]. Predictors of post-stroke depression in the rehabilitation setting include increasing physical disability, cognitive impairment, and stroke severity [551]. There is no consensus on the optimal method for screening or diagnosis of post-stroke depression. Standard depression screening tools may be inappropriate for patients with aphasia or cognitive impairment [554, 555].

Antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs) and heterocyclics can improve mood after stroke [556, 557], but there is less evidence that these agents can effect full remission of a major depressive episode or prevent depression. SSRIs are better tolerated than heterocyclics [558]. There is no good evidence to recommend psychotherapy for treatment or prevention of post-stroke depression [559], although such therapy can elevate mood. There is a lack of robust evidence regarding the effect of treating post-stroke depression on rehabilitation or functional outcomes.

Emotionalism is a distressing symptom for patients and carers. SSRIs may reduce emotional outbursts but effects on quality of life are not clear [560].
Pain and spasticity

Post-stroke shoulder pain (PSSP) is common [561], especially in patients with impaired arm function and poor functional status, and is associated with poorer outcome. Passive movement of a paretic limb may be preventive [562]. Electrical stimulation is commonly used for treatment, but its efficacy is unproven [563]. A Cochrane systematic review found insufficient data to recommend the use of orthotic devices for shoulder subluxation, despite a trend towards efficacy for arm strapping of the affected limb [564].

Lamotrigine and gabapentin may be considered for neuropathic pain [565]. They appear to be well tolerated, but cognitive side effects should be considered.

Spasticity in the chronic phase may adversely affect ADL and quality of life [566]. Posture and movement therapy, relaxing therapy, splints and supports are all commonly employed, but a sound evidence base is lacking [567]. Pharmacotherapy with botulinum toxin has proven effects on muscle tone in arms and legs, but functional benefits are less well studied [568-570]. Oral agents are limited in their use because of side effects [571].

Eligibility for rehabilitation

An important predictor of rehabilitation outcome is initial stroke severity [550]. Pre-stroke disability is clearly also a strong determinant of outcome [572]. Other factors, such as sex [573], stroke aetiology [574], age [575], and topography of lesion [576], have all been studied as potential predictors of rehabilitation outcome; however, there is no evidence that these non-modifiable factors should influence decisions on rehabilitation [577]. Admission to a dedicated stroke unit improves outcomes for all strokes irrespective of age, sex, and severity [61].

Exclusion from rehabilitation on the basis of pre-stroke dependence remains a contentious issue [578, 579]. Patients with the most severe cognitive or physical impairments have been excluded from most rehabilitation trials, and therefore caution is required in extrapolating results to this group [580]. Limited data suggest that active rehabilitation allows severely disabled patients to return home [581, 582]. For those unable to participate actively, passive movements to prevent contractures or pressure sores have been recommended [2].

Appendix

ESO (EUSI) Recommendation Writing Committee
Chair: Werner Hacke, Heidelberg, Germany
Co-chairs: Marie-Germaine Bousser, Paris, France; Gary Ford, Newcastle, UK

Education, referral and emergency room
Co-chairs: Michael Brainin, Krems, Austria; José Ferro, Lisbon, Portugal
Members: Charlotte Cordonnier, Lille, France; Heinrich P. Mattle, Bern, Switzerland; Keith Muir, Glasgow, UK; Peter D. Schellinger, Erlangen, Germany
Substantial assistance received from: Isabel Henriques, Lisbon, Portugal

Stroke units
Co-chairs: Hans-Christoph Diener, Essen, Germany; Peter Langhorne, Glasgow, UK
Members: Antony Davalos, Barcelona, Spain; Gary Ford, Newcastle, UK; Veronika Skvortsova, Moscow, Russia

Imaging and diagnostics
Co-chairs: Michael Hennerici, Mannheim, Germany; Markku Kaste, Helsinki, Finland
Members: Hugh S. Markus, London, UK; E. Bernd Ringelstein, Münster, Germany; Rüdiger von Kummer, Dresden, Germany; Joanna Wardlaw, Edinburgh, UK
Substantial assistance received from: Oliver Müller, Heidelberg, Germany

Prevention
Co-chairs: Philip Bath, Nottingham, UK; Didier Leys, Lille, France
Members: Álvaro Cervera, Barcelona, Spain; László Csiba, Debrecen, Hungary; Jan Lodder, Maastricht, The Netherlands; Nils Gunnar Wahlgren, Stockholm, Sweden

General treatment
Co-chairs: Christoph Diener, Essen, Germany; Peter Langhorne, Glasgow, UK
Members: Antony Davalos, Barcelona, Spain; Gary Ford, Newcastle, UK; Veronika Skvortsova, Moscow, Russia

Acute treatment and treatment of complications
Co-chairs: Angel Chamorro, Barcelona, Spain; Bo Norrving, Lund, Sweden
Members: Valerica Caso, Perugia, Italy; Jean-Louis Mas, Paris, France; Victor Obach, Barcelona, Spain; Peter A. Ringleb, Heidelberg, Germany; Lars Thomsen, Bergen, Norway

Rehabilitation
Co-chairs: Kennedy Lees, Glasgow, UK; Danilo Toni, Rome, Italy
Members: Stefano Paolucci, Rome, Italy; Juhani Sivenius, Kuopio, Finland; Katharina Stibrant Sunnerhagen, Göteborg, Sweden; Marion F. Walker, Nottingham, UK

Substantial assistance received from: Yvonne Teuschl, Isabel Henriques, Terence Quinn

We want to thank Dr Michael Shaw for his assistance during the preparation of this manuscript.

Glossary

ADC  apparent diffusion coefficient
ADL  activities of daily living
AF   atrial fibrillation
AR   absolute risk
BP   blood pressure
CAS  carotid artery stenting
CEA  carotid endarterectomy
CE-MRA contrast-enhanced MR angiography
CI   confidence interval
CSF  cerebral spinal fluid
CT   computed tomography
CTA  computed tomography angiography
CV   cardiovascular
DSA  digital subtraction angiography
DVT  deep vein thrombosis
DWI  diffusion-weighted imaging
ECG  electrocardiography
ED   emergency department
EEG  electroencephalography
EFNS European Federation of Neurological Societies
EMS emergency medical service
ESO European Stroke Organisation
EUSI European Stroke Initiative
FLAIR fluid attenuated inversion recovery
GCP good clinical practice
HR hazard ratio
ICA internal carotid artery
ICP intracranial pressure
INR international normalized ratio
i.v. intravenous
LDL low density lipoprotein
MCA middle cerebral artery
MI myocardial infarction
MRA magnetic resonance angiography
MRI magnetic resonance imaging
mRS modified Rankin score
NASCET North American Symptomatic Carotid Endarterectomy Trial
NG nasogastric
NIHSS National Institutes of Health Stroke Scale
NINDS National Institute of Neurological Disorders and Stroke
NNH numbers needed to harm
NNT numbers needed to treat
OSA obstructive sleep apnoea
OR odds ratio
OT occupational therapy
PE pulmonary embolism
PEG percutaneous enteral gastrostomy
PFO patent foramen ovale
pUK pro-urokinase
QTc heart rate corrected QT interval
RCT randomized clinical trial
RR relative risk
rtPA recombinant tissue plasminogen activator
SLT speech and language therapy
SSRI selective serotonin reuptake inhibitor
TCD transcranial Doppler
TOE transoesophageal echocardiography
TIA transient ischaemic attack
TTE transthoracic echocardiography
UFH unfractionated heparin
Conflicts of interest

P. Bath: Research support from Boehringer-Ingelheim; speakers honoraria from AZ, Boehringer-Ingelheim; consultancy/advisory board AZ, BI, Lundbeck, ReNeurone, Servier.

M. G. Bousser: Research grants and support from SANOFI Servier; research support from Novo-Nordisk, Paion; consultancy/advisory board Servier, Sanofi.

M. Brainin: Research grant from Ebewe, Novo Nordisk; research support from Boehringer-Ingelheim, Sanofi-Aventis, Solvaypharma; speakers’ honoraria, Novartis, Boehringer-Ingelheim, Sanofi-Aventis, Ebewe, Solvaypharma; consultancy/advisory board, Boehringer-Ingelheim, Ebewe.

A. Chamorro: Speaker’s honoraria from BMS, Sanofi, Boehringer; consultancy/advisory board Servier, Sanofi.

L. Csiba: Research grant from UCB EGIS Zrt, Gedeon Richter, Aventis; speakers’ honoraria from Boehringer-Ingelheim, PAION, Lundbeck A/S, Pfizer, EGIS Zrt, Sanofi-Aventis, Novo-Nordisk A/S, Astra-Zeneca, Johnson & Johnson, Gedeon Richter, MSD, UCB, Convex; consultancy/advisory board, Pfizer Hungary, Johnson & Johnson, Paion, Gedeon Richter, Boehringer-Ingelheim.

A. Davalos: Speakers’ honoraria from Ferrer, PAION, Lundbeck, Pfizer, Astra-Zeneca, BMS, Thrombogenics, Boehringer-Ingelheim; consultancy/advisory board, Ferrer, PAION, Lundbeck, Pfizer, Astra-Zeneca, BMS, Thrombogenics, Boehringer-Ingelheim.

H. C. Diener: Research grant from AstraZeneca, GSK, Boehringer-Ingelheim, Novartis, Janssen-Cilag, Sanofi-Aventis; research support from German Research Council (DFG), German Ministry of Education and Research (BMBF), European Union, Bertelsmann Foundation, Heinz-Nixdorf Foundation; speakers’ honoraria from Abbott, AstraZeneca, Bayer Vital, Boehringer-Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, MSD, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Servier, Solvay, Wyeth, Yamaguchi; consultancy/advisory board, Abbott, Astra-Zeneca, Bayer Vital, Boehringer-Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, MSD, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Servier, Solvay, Wyeth, Yamaguchi.

J. M. Ferro: Research grant from Tecnofar, Boehringer-Ingelheim; research support from Bayer, Sanofi-Aventis; speaker’s honoraria from Tecnofar, Ferrer; consultancy/advisory board, Sanofi-Aventis, Uriach, Servier, Ferrer.

G. Ford: Research grant from Boehringer-Ingelheim, Servier, NTI, Lundbeck, Paion; speakers’ honoraria from Boehringer-Ingelheim, AstraZeneca; consultancy/advisory board, Boehringer-Ingelheim.

W. Hacke: Research grant from DFG, BMBF; speakers’ honoraria from Sanofi Aventis, Novo-Nordisk, Ferrer, Boehringer-Ingelheim; consultancy/advisory board, Sanofi Aventis, BMS, Novo-Nordisk, Boehringer-Ingelheim, Nuvelo, Novothera, Bayer, J&J, Brainsgate, Paion, Ferrer, Lilly, Centocor, ImarX.

M. G. Hennerici: Research grants from DFG, BMBF, EU specific foundations; research support from RCTs grants; speaker’s honoraria, several studies from Pfizer, Boehringer, Sanofi, Bayer, Knoll, Janssen, etc; consultancy/advisory board, SPARCL, ESTAT, ECASSII, etc.


P. Langhorne: Speakers’ honoraria, Previous Boehringer, Pfizer, Sanofi.

K. Lees: Research grant from MRC, Stroke Association, Lundbeck, AstraZeneca, Boehringer-Ingelheim, Servier, NTI, Brainsgate; speakers’ honoraria, AstraZeneca, BMS, NTI, Sanofi, Paion, Forest, Lundbeck, Boehringer-Ingelheim, GlaxoSmithKline, Mitsubishi, Bayer, Ferrer, Novonordisk, DPharm, Brainsgate, Thrombogenics, Servier; ownership interest, NTI; consultancy/advisory board, see honoraria.

D. Leys: Research grants from BMS, AstraZeneca, Boehringer-Ingelheim, NovoNordisk, Servier; consultancy/advisory board, Paion.

J. Lodder: Research support and speakers’ honoraria from Boehringer-Ingelheim; consultancy/advisory board, Boehringer-Ingelheim.

H. Markus: Speakers’ honoraria from Sanofi; consultancy/advisory board, Sanofi, GE, Boehringer.

J. L. Mas: Research grant from Sanofi, BMS; speakers’ honoraria, Sanofi, BMS, Servier, Boehringer, Johnson & Johnson; consultancy/advisory board, Sanofi, BMS, Servier.

H. Mattle: Research grant from AGA Medical, Bayer-Schering; research support from Biogen-Idec, Merck-
Serono, Sanofi-Aventis; speakers’ honoraria, Servier, Pfizer, Sanofi-Aventis, Bristol Myers Squib, Boehringer-Ingelheim; ownership interest, Novartis, Roche; consultancy/advisory board, Pfizer, Merck Sharp & Dohme.

K. W. Muir. Research grants from Shire Pharmaceuticals, BMS, Sanofi; speakers’ honoraria from Novo Nordisk, Sanofi; consultancy advisory board, GSK, Paion, Lilly, Novo Nordisk, ThromboGenics.

B. Norrving: Speakers’ honoraria from MSD, SHIRE; consultancy/advisory board, Boehringer, Pfizer, Servier.

S. S. Paolucci: Speakers’ honoraria from Boehringer-Ingelheim, Eli Lilly.

B. Ringelstein: Research grants from Novartis, NTI (Ancrod) and INC Research; speakers’ honoraria, Boehringer-Ingelheim, Sanofi-Aventis, Altana, UCB, BMS; consultancy/advisory board, INC Research, AstraZeneca, Bayer-Schering Health Care.

P. A. Ringleb: Speakers’ honoraria from Paion, Sanofi, Boehringer; consultancy/advisory board, Paion.

P. D. Schellinger: Speaker’s honoraria from Boehringer-Ingelheim, Paion, Sanofi-Aventis, Ferrer, ImarX, Solvay, Altana; consultancy/advisory board, Boehringer-Ingelheim, Ferrer, ImarX.

J. Sivenius: Speakers’ honoraria from Boehringer-Ingelheim, Pfizer; consultancy/advisory board, Boehringer-Ingelheim, Pfizer.

V. Skvortsova: Speakers’ honoraria from Boehringer-Ingelheim, Ebewe, Sanofi Aventis; consultancy/advisory board, Boehringer-Ingelheim.

L. Thomassen: Restricted research funding from Boehringer-Ingelheim; Speakers’ honoraria, Pfizer, Boehringer-Ingelheim, Sanofi, AstraZeneca, MSD, etc.; consultancy/advisory board, Sanofi, Boehringer, Gore reduce trial.

D. Toni: Research grants from Boehringer-Ingelheim, SHIRE; speaker’s honoraria from Boehringer-Ingelheim, Novo Nordisk, Sanofi-Aventis, Astra-Zeneca; consultancy/advisory board, Boehringer-Ingelheim.


N. Wahlgren: Research grant from Boehringer-Ingelheim; research support from Boehringer-Ingelheim, Bayer, AstraZeneca, Sanofi-Aventis, Novo-Nordisk, Thrombogenics, Servier; speakers’ honoraria, Boehringer-Ingelheim, Bayer, Astra-Zeneca, Sanofi-Aventis, Novo-Nordisk; consultancy/advisory board, Boehringer-Ingelheim, Bayer, AstraZeneca, Sanofi-Aventis, Novo-Nordisk.

These statements were valid at the time of the publication of this guideline in the journal Cerebrovascular Diseases in 2008.

References

Important references for special topics are marked with asterisks.


31. Mandelzweig L, Goldbourt U, Boyko V, Tanne D. Perceptual, social, and behavioral factors associated with delays


CHAPTER 9 Acute stroke


328. *Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT):


CHAPTER 9 Acute stroke


Major Neurological Diseases

induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical
trial. JAMA 2006;296:2095–104.
525. *Legg LA, Drummond AE, Langhorne P. Occupational
CD003585.
patient data meta-analysis of randomized controlled trials of
community occupational therapy for stroke patients. Stroke
2004;35:2226–32.
pilot controlled trial of an occupational therapy interven-
tion for residents with stroke in UK care homes. Stroke
2006;37:2336–41.
528. Bath PMW, Bath-Hextall FJ, Smithard DG. Interventions
for dysphagia in acute stroke. Cochrane Database Syst Rev
Dysphagia therapy following stroke: a controlled trial.
530. Engelter ST, Gostynski M, Papa S, et al. Epidemiology of
aphasia attributable to first ischemic stroke: incidence,
severity, fluency, etiology, and thrombolysis. Stroke
531. *Sellars C, Hughes T, Langhorne P. Speech and language
therapy for dysarthria due to non-progressive brain
532. *Greener J, Enderby P, Whurr R. Speech and language
therapy for aphasia following stroke. Cochrane Database
533. Robey RR. The efficacy of treatment for aphasic persons: a
534. Robey RR. A meta-analysis of clinical outcomes in the
treatment of aphasia. J Speech Lang Hear Res 1998;41:
172–87.
induced therapy of chronic aphasia after stroke. Stroke
536. Bhogal SK, Teasell R, Speechley M. Intensity of aphasia
537. *Stroke Liaison Workers Collaboration. Meta-analysis of
stroke liaison workers for patients and carers: results by
538. O’Mahony PG, Rodgers H, Thomson RG, Dobson R, James
OE. Satisfaction with information and advice received by
539. *Forster A, Young I, Langhorne P. Medical day hospital
care for the elderly versus alternative forms of care. Cochrane
Major Neurological Diseases


